GPR35 Modulators

Compounds targeting GPR35 offer a novel approach to treating inflammatory bowel diseases by modulating immune responses, addressing the limitations of current therapies and improving treatment outcomes for IBD patients.

JP7588077B2Active Publication Date: 2024-11-21PROMETHEUS BIOSCIENCES INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021543122
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-30
Filing Date
2020-01-23
Publication Date
2024-11-21
Estimated Expiration
2040-01-23

AI Technical Summary

Technical Problem

Current treatment options for inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis are limited and ineffective for many patients, particularly those who do not respond to anti-TNF therapy, necessitating targeted treatments that address the underlying immunopathogenesis of IBD.

Method used

Development of compounds of formula (I), (I'), or (I'') or their pharmaceutically acceptable salts and solvates, which modulate the activity of GPR35, a receptor involved in inflammatory regulation, offering potential therapeutic benefits for IBD.

Benefits of technology

These compounds provide targeted treatment options for IBD, potentially improving response rates and managing disease severity in patients who do not respond to conventional therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588077000001
    Figure 0007588077000001
  • Figure 0007588077000002
    Figure 0007588077000002
  • Figure 0007588077000003
    Figure 0007588077000003
Patent Text Reader

Abstract

Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 62 / 796,459, filed January 24, 2019, U.S. Provisional Patent Application No. 62 / 873,703, filed July 12, 2019, and U.S. Provisional Patent Application No. 62 / 928,223, filed October 30, 2019, all of which are incorporated by reference in their entirety herein. [Background technology]

[0002] Millions of people suffer from inflammatory diseases or illnesses. A prominent inflammatory disease is inflammatory bowel disease (IBD). There are two common forms of IBD, Crohn's disease (CD) and ulcerative colitis (UC), which are chronic and recurrent inflammatory diseases of the digestive tract. Each of these forms has a variety of sub-symptoms that are present in subpopulations of CD and UC patients. Some CD and UC patients experience a rapid onset of symptoms, while others experience a relatively slow onset.

[0003] There are few treatment options available for patients suffering from IBD. Moreover, choosing the appropriate treatment for any individual patient at a given stage of their disease is complicated by the unpredictability of each individual's prognosis. Current treatment regimens include one or more of anti-inflammatory drug therapy (e.g., corticosteroids) and immunomodulatory therapy (e.g., anti-TNF therapy). However, nearly half of all patients treated with anti-TNF therapy either do not respond to induction of therapy or experience loss of response to treatment after a period during which disease severity has progressed significantly. Thus, there remains a significant need for targeted, effective treatment options that respond to the underlying immunopathogenesis of IBD. Summary of the Invention

[0004] In one aspect, provided herein is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof:

[0005] [ka] During the ceremony, R 1 is -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R 9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl,

[0006] [ka] , or one, two, or three R's 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -NO 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth,

[0007] [ka] and; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-R 9 , -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 , C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, and C1-9 heteroaryl; 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, -C(O)OR 10 , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl and -C 1-6 Alkyl-C 2-9 Heterocycloalkyl is a halogen, -C(O)OR 10 , C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 is -C(O)OR 7 , -C(O)NHS(O) 2 N(R 10 ) 2 ,

[0008] [ka] and; R 7 are independently H and C 1-6 alkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O)2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR 11 , -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 , -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 )2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are each independently H and C 1-6 alkyl; R 13 are each independently 1-6 alkyl; m is 1, 2, 3, or 4; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 0, 1, 2, 3, or 4.

[0009] In another aspect, provided herein is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof:

[0010] [ka] During the ceremony, R 1 -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R 9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C 1-6Alkyl-OH, C 3-8 Cycloalkyl,

[0011] [ka] , or one, two, or three R 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 )2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth,

[0012] [ka] and; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-R 9 , -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 , C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 is -C(O)OR 7 , -C(O)NHS(O) 2 N(R 10 ) 2 ,

[0013] [ka] and; R 7 are each independently H and C 1-6 alkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 , -C(O)R 12, and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; q is 0, 1, 2, 3, or 4.

[0014] In another aspect, provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof:

[0015] [ka] During the ceremony, R 1 is -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R 9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl,

[0016] [ka] , or one, two, or three R 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth,

[0017] [ka] and; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 is -C(O)OR 7 , -C(O)NHS(O) 2 N(R 10 ) 2 ,

[0018] [ka] and; R 7 are each independently H and C 1-6 alkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; q is 0, 1, 2, 3, or 4.

[0019] In some embodiments, there is a compound of formula (I), (I′), or (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0020] [ka] In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0, 1, or 2. In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and

[0021] [ka] In some embodiments selected from the group consisting of compounds of formula (I), (I′), or (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 5 are each independently -C(O)OR 10In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 9 is -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are each independently H and C 1-6 In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1 or 2. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where p is 2. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8In some embodiments, there is provided a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where R 1 is one or two R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 and R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and triazinyl. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8and R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl and pyrimidinyl. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently a halogen, -C(O)OR 10 , C 1-6 Alkyl, and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments are compounds of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl selected from pyridinyl and pyrimidinyl. In some embodiments are compounds of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are independently H, C 1-6Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein two R 10 , and the nitrogen atom to which they are attached together form C 1-6and forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 groups independently selected from alkyl, oxo, and -C(O)OH. In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein two R 10 and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is —C(O)OH. In some embodiments, there is a compound of formula (I), (I′), or (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth

[0022] [ka] In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH3 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, where R 3 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 3 are each independently halogen, -OR 9 , and C 1-6 In some embodiments, there is a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 3 are -OR 9 and R 9 is C 3-8 In some embodiments, there is a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0.

[0023] In another aspect, described herein is a pharmaceutical composition comprising a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient.

[0024] In another aspect, there is a method of treating inflammatory bowel disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a method of treating inflammatory bowel disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is selected from Crohn's disease, ulcerative colitis, and perianal Crohn's disease. Optionally, the ulcerative colitis is a severe form of ulcerative colitis. Optionally, the severe form of ulcerative colitis is medically refractory ulcerative colitis.

[0025] In another aspect, described herein is a method of modulating GPR35 activity comprising contacting GPR35, or a portion thereof, with a compound of formula (I), (I'), or (I''), or a pharma- ceutically acceptable salt or solvate thereof.

[0026] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] definition

[0028] In the context of this disclosure, a number of terms will be utilized.

[0029] Unless otherwise specified, technical and scientific terms used herein have the same meaning as commonly understood to which the claimed subject matter belongs. In the event of a plurality of definitions for terms herein, the definitions in this section prevail. All patents, patent applications, publications, and published nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) referenced herein are incorporated by reference. When a URL or other such identifier or address is mentioned, it is understood that such identifiers can change and that particular information on the Internet can come and go, but equivalent information can be found by an Internet search. Reference thereto evidences the availability and public dissemination of such information.

[0030] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to be limiting of the subject matter of any application. In this application, the use of the singular includes the plural unless specifically stated otherwise. As used within the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless specifically stated otherwise. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is non-limiting.

[0031] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0032] Definitions of standard chemical terms may be found in reference sources, including, but not limited to, Carey and Sundberg "Advanced Organic Chemistry 4th Ed." Vols. A(2000) and B(2001), Plenum Press, New York. Unless otherwise specified, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology.

[0033] Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory methods and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are art-recognized. Standard techniques may be used for chemical synthesis, chemical analysis, drug preparation, formulation, and delivery, and patient treatment. Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reaction and purification techniques may be performed, for example, using kits per manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be performed in a generally conventional manner and as described in various general and more specific references cited and discussed throughout this specification.

[0034] It will be understood that the methods and compositions described herein are not limited to the particular methods, protocols, cell lines, constructs, and reagents described herein, and as such may vary. Furthermore, the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods, compounds, compositions described herein.

[0035] As used herein, C1-Cx includes C1-C2, C1-C3...C1-Cx. C1-Cx refers to the number of carbon atoms that make up the moiety it designates (excluding any optional substituents).

[0036] An "alkyl" group refers to an aliphatic hydrocarbon group. The alkyl group may or may not contain units of unsaturation. The alkyl moiety may be a "saturated alkyl" group, meaning that the alkyl moiety does not contain units of unsaturation (i.e., carbon-carbon double bonds or carbon-carbon triple bonds). The alkyl group may also be an "unsaturated alkyl" moiety, meaning that the alkyl group contains at least one unit of unsaturation. The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.

[0037] An "alkyl" group can have 1 to 6 carbon atoms (whenever alkyl appears herein, a number range such as "1 to 6" refers to each integer in the given range; for example, "1 to 6 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 6 carbon atoms, but this definition also covers occurrences of the term "alkyl" where no number range is specified). The alkyl groups of the compounds described herein are defined as "C 1 -C 6 Alkyl" or a similar designation. 1 -C 6 "Alkyl" means that there are 1 to 6 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, N-propyl, iso-propyl, N-butyl, iso-butyl, sec-butyl, t-butyl, N-pentyl, iso-pentyl, neo-pentyl, hexyl, propen-3-yl (allyl), cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl. Alkyl groups can be substituted or unsubstituted. Depending on the structure, alkyl groups can be monoradicals or diradicals (i.e., alkylene groups).

[0038] "Alkoxy" refers to the group "-O-alkyl" where alkyl is as defined herein.

[0039] The term "alkenyl" refers to a type of alkyl group in which the first two atoms of the alkyl group form a double bond that is not part of an aromatic group. That is, an alkenyl group is one in which the atoms -C(R)=CR 2 where R refers to the remainder of the alkenyl group, which may be the same or different. Non-limiting examples of alkenyl groups include -CH=CH 2 , -C(CH 3 )=CH 2 , -CH=CHCH 3 , -CH=C(CH 3 ) 2 , and -C(CH 3 )=CHCH 3 The alkenyl moiety may be branched, straight chain, or cyclic (in either case, it is also known as a "cycloalkenyl" group). The alkenyl group may have 2 to 6 carbons. The alkenyl group may be substituted or unsubstituted. Depending on the structure, the alkenyl group may be a monoradical or a diradical (i.e., an alkenylene group).

[0040] The term "alkynyl" refers to a type of alkyl group in which the first two atoms of the alkyl group form a triple bond. That is, an alkynyl group begins with the atom -C≡CR, where R refers to the remainder of the alkynyl group. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH 3 , -C≡CCH 2 CH 3 , and -C≡CCH 2 CH 2 CH 3 The "R" portion of the alkynyl moiety can be branched, straight chain, or cyclic. Alkynyl groups can have 2 to 6 carbons. Alkynyl groups can be substituted or unsubstituted. Alkynyl groups can be monoradicals or diradicals (i.e., alkynylene groups), depending on the structure.

[0041] "Amino" means -NH 2 Refers to the base.

[0042] The term "alkylamine" or "alkylamino" refers to the group -N(alkyl)xHy, where alkyl is as defined herein and x and y are selected from the group: x=1, y=1, and x=2, y=0. When x=2, the alkyl groups, together with the nitrogen to which they are attached, can optionally form a cyclic ring system. "Dialkylamino" refers to -N(alkyl)xHy. 2 refers to the group, where alkyl is as defined herein.

[0043] The term "aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. Aromatic rings can be formed from 5, 6, 7, 8, 9, or more than 9 atoms. Aromatics can be optionally substituted. The term "aromatic" includes both aryl (e.g., phenyl, naphthalenyl) and heteroaryl (e.g., pyridinyl, quinolinyl) groups.

[0044] As used herein, the term "aryl" refers to an aromatic ring in which each of the atoms forming the ring is a carbon atom. An aryl ring can be formed by 5, 6, 7, 8, 9, or more than 9 carbon atoms. An aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl and naphthalenyl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group).

[0045] "Carboxy" means -CO 2H. In some embodiments, the carboxy moiety may be replaced with a "carboxylic acid bioisostere," which refers to a functional group or moiety that exhibits similar physical and / or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties as a carboxylic acid group. A compound that includes a carboxylic acid moiety can have the carboxylic acid moiety replaced with a carboxylic acid bioisostere and have similar physical and / or biological properties compared to a compound that includes a carboxylic acid. For example, in one embodiment, a carboxylic acid bioisostere will ionize at physiological pH to about the same extent as a carboxylic acid group. Examples of carboxylic acid bioisosteres include, but are not limited to,

[0046] [ka] etc.

[0047] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic radical, in which each of the atoms forming the ring (i.e., skeletal atoms) is a carbon atom. Cycloalkyls can be saturated or partially unsaturated. Cycloalkyls can be fused with an aromatic ring (in which case the cycloalkyl is attached via a non-aromatic ring carbon atom). Cycloalkyl groups include groups having 3 to 10 ring atoms.

[0048] The terms "heteroaryl" or, alternatively, "heteroaromatic" refer to an aryl group that contains one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. An N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.

[0049] A "heterocycloalkyl" or "heteroalicyclic" group refers to a cycloalkyl group in which at least one skeletal ring atom is a heteroatom selected from nitrogen, oxygen, and sulfur. The radical may be fused with an aryl or heteroaryl. The term heteroalicyclic also includes all cyclic forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. Unless otherwise specified, a heterocycloalkyl has 2-10 carbons in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it is noted that the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (i.e., skeletal atoms of the heterocycloalkyl ring) (including heteroatoms) that make up the heterocycloalkyl.

[0050] The term "halo" or alternatively "halogen" means fluoro, chloro, bromo, and iodo.

[0051] The term "haloalkyl" refers to an alkyl group that is substituted with one or more halogens. The halogens can be the same or different. A non-limiting example of a haloalkyl is -CH 2 Cl, -CF 3 , -CHF 2 , -CH 2 CF 3 , -CF 2 CF 3 etc.

[0052] The terms "fluoroalkyl" and "fluoroalkoxy" include alkyl and alkoxy groups, respectively, that are substituted with one or more fluorine atoms. A non-limiting example of a fluoroalkyl is -CF 3 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , -CF 2 CF 3 , -CF 2 CF 2 CF 3 , -CF(CH 3 ) 2A non-limiting example of a fluoroalkoxy group is -OCF 3 , -OCHF 2 , -OCH 2 F, -OCH 2 CF 3 , -OCF 2 CF 3 , -OCF 2 CF 2 CF 3 , -OCF(CH 3 ) 2 etc.

[0053] The term "heteroalkyl" refers to an alkyl radical in which one or more skeletal atoms are selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof. The heteroatom may be located at any interior position of the heteroalkyl group. Examples include, but are not limited to, -CH 2 -O-CH 3 , -CH 2 -CH 2 -O-CH 3 , -CH 2 -NH-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -N(CH 3 )-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH2-CH 2 -N(CH 3 )-CH 3 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 -S(O)-CH 3 , -CH 2 -CH 2 -S(O) 2 -CH 3 , -CH 2 -NH-OCH 3 , -CH 2 -O-Si(CH 3 )3 , -CH 2 -CH=N-OCH 3 , and -CH=CH-N(CH 3 )-CH 3 In addition, up to two heteroatoms may be, for example, -CH 2 -NH-OCH 3 and -CH 2 -O-Si(CH 3 ) 3 etc. Excluding the number of heteroatoms, a "heteroalkyl" may have from 1 to 6 carbon atoms.

[0054] The term "bond" or "single bond" refers to a chemical bond between two atoms or two moieties where the atoms joined by the bond are considered to be part of a larger substructure.

[0055] The term "moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is often recognized as a chemical substance that is embedded in or appended to a molecule.

[0056] As used herein, the substituent "R" appearing alone and without a number designation refers to a substituent selected from among alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded via a ring carbon), and heterocycloalkyl.

[0057] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances where it does not occur.

[0058] The term "optionally substituted" or "substituted" means that the referenced group is an alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkyne, C 1 -C6 Alkyl alkyne, halo, acyl, acyloxy, -CO 2 H, -CO 2 -Alkyl, nitro, haloalkyl, fluoroalkyl, and mono- and di-substituted amino groups (e.g., -NH 2 , -NHR, -N(R) 2 ) as well as protected derivatives thereof. S R S where L S are each independently a single bond, -O-, -C(=O)-, -S-, -S(=O)-, or -S(=O) 2 -, -NH-, -NHC(O)-, -C(O)NH-, S(=O) 2 NH-, -NHS(=O) 2 , -OC(O)NH-, -NHC(O)O-, -(C 1 -C 6 alkyl)- or -(C 2 -C 6 alkenyl)-; and R S are independently H, (C 1 -C 6 Alkyl), (C 3 -C 8 cycloalkyl), aryl, heteroaryl, heterocycloalkyl, and C 1 -C 6 The protecting groups that may form the protective derivatives of the above substituents can be found in sources such as Greene and Wuts, above.

[0059] As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0060] As used herein, the term "therapeutically effective amount" refers to an amount of a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id) that, when administered to a mammal in need thereof, is effective to at least partially treat a disease described herein.

[0061] The term "modulate" encompasses either a decrease or an increase in activity, depending on the target molecule.

[0062] The term "activator" is used herein to denote any molecular species that, when administered locally, results in activation of the indicated receptor, regardless of whether the molecular species itself binds to the receptor or whether a metabolic product of the molecular species binds to the receptor. Thus, an activator may be a ligand of the receptor, or it may be an activator that is metabolized to a ligand of the receptor, i.e., a metabolite that is formed in the tissue and is the actual ligand.

[0063] The term "patient" or "mammal" refers to a human, non-human primate, canine, feline, bovine, ovine, porcine, murine, or other veterinary or laboratory mammal. One of skill in the art will recognize that a treatment that reduces the severity of a condition in one species of mammal is predictive of the effectiveness of the treatment on another species of mammal.

[0064] "Pharmaceutically acceptable salt" includes both acid and base addition salts. Any one of the pharmaceutically acceptable salts of the compounds described herein is intended to include any and all pharmaceutically suitable salt forms. The preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0065] "Pharmaceutically acceptable acid addition salts" refers to salts which retain the biological effectiveness and properties of the free bases, which salts are not biologically or otherwise undesirable, and are formed with inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, hydroiodic, hydrofluoric, phosphorous, etc. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic, alkanediol (alkanediol) acids, aromatic acids, aliphatic and aromatic sulfonic acids, and salts with, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, P-toluenesulfonic acid, salicylic acid, etc. Thus, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Salts of amino acids such as arginate, gluconate, and galacturonate are also contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting the free base with a sufficient amount of the desired acid to produce the salt.

[0066] "Pharmaceutically acceptable base addition salts" refer to salts that retain the biological effectiveness and properties of the free acid, which are not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. In some embodiments, pharma-ceutically acceptable base addition salts are formed with metals or amines, such as alkali, alkaline earth metals, or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., supra.

[0067] As used herein, "treatment" or "treat" or "alleviate" or "ameliorate" are used interchangeably herein. Such terms refer to an approach to obtain a beneficial or desired result, including, but not limited to, a therapeutic effect and / or a preventive effect. A "therapeutic effect" refers to the eradication or amelioration of the underlying disease being treated. Furthermore, a therapeutic effect is achieved by the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disease, such that an improvement is observed in the patient, even though the patient still suffers from the underlying disease. In the case of a preventive effect, the composition is administered to a patient at risk of developing a particular disease, or a patient in whom one or more of the physiological symptoms of the disease are reported, even if a diagnosis of the disease has not been made.

[0068] As used herein, "medically refractory" or "refractory" as used herein refers to the failure of standard treatments to induce disease remission. In some embodiments, the disease includes inflammatory diseases disclosed herein. Non-limiting examples of refractory inflammatory diseases include refractory Crohn's disease and refractory ulcerative colitis (e.g., medically refractory UC, or mrUC). Non-limiting examples of standard treatments include glucocorticosteriods, anti-TNFα therapy, anti-A4-B7 therapy (vedolizumab), anti-IL 12P40 therapy (ustekinumab), thalidomide, and cytoxin.

[0069] G protein-coupled receptor 35 (GPR35) G protein-coupled receptor 35 (GPR35) is a receptor for kynurenic acid, an intermediate in the tryptophan metabolic pathway. GPR35 mediates calcium mobilization and inositol phosphate production. GPR35, and nucleic acids encoding GPR35, are characterized by NCBI Entrez GENE ID 2859. Studies have shown that GPR35 is associated with inflammatory regulation, either by the presence of the receptor on the surface of immune-specific cells or by agonist activation leading to altered immune responses. Thus, it is hypothesized that GPR35, and nucleic acids encoding GPR35, play a role in the pathology of inflammatory diseases, making GPR35 an attractive therapeutic target for treating inflammatory diseases or conditions.

[0070] The compounds of formula (I), (I'), or (I'') described herein are GPR35 modulators. In some embodiments, the compounds of formula (I), (I'), or (I'') described herein are GPR35 agonists. In some embodiments, the compounds of formula (I), (I'), or (I'') described herein are GPR35 inverse agonists. In some embodiments, the compounds of formula (I), (I'), or (I'') described herein are GPR35 antagonists. The compounds of formula (I), (I'), or (I'') described herein, and compositions comprising these compounds, are useful for treating inflammatory bowel disease.

[0071] In some embodiments, provided herein is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof:

[0072] [ka] During the ceremony, R 1 is -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl,

[0073] [ka] , or one, two, or three R's 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -NO 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O)2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth,

[0074] [ka] and; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2, -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-R 9 , -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 , C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, -C(O)OR 10 , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl and -C 1-6 Alkyl-C 2-9 Heterocycloalkyl is a halogen, -C(O)OR 10 , C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 is -C(O)OR 7 , -C(O)NHS(O) 2 N(R 10 ) 2 ,

[0075] [ka] and; R 7 are independently H and C 1-6 alkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 , -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are each independently H and C 1-6 alkyl; R 13 are each independently 1-6 alkyl; m is 1, 2, 3, or 4; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 0, 1, 2, 3, or 4.

[0076] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth

[0077] [ka] In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0078] [ka] and p is 0, 1, or 2. In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0079] [ka] and p is 0. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0080] [ka] and p is 1. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0081] [ka] and p is 2. In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0082] [ka] and p is 1 or 2. In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0083] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0084] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0085] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0086] [ka] where p is 1 or 2, and R5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0087] [ka] where p is 1 or 2, and R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0088] [ka] where p is 1 or 2, and R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0089] [ka] where p is 1 or 2, and R 5 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0090] [ka] where p is 1 or 2, and R 5 are each independently -C(O)OR 10 Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0091] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0092] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 Selected from R 9 is -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0093] [ka] where p is 1 and R 5 is independently selected from:

[0094] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, there is a compound of formula (I"), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 and R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and triazinyl. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 and R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl and pyrimidinyl. In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8are each independently a halogen, -C(O)OR 10 , C 1-6 Alkyl, and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl selected from pyridinyl and pyrimidinyl.

[0095] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C1-6 and forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 groups independently selected from alkyl, oxo, and -C(O)OH. In some embodiments, there is a compound of formula (I"), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I'') or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0096] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6and forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 groups independently selected from alkyl, oxo, and -C(O)OH. In some embodiments, there is a compound of formula (I"), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I'') or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0097] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is -C(O)OH.

[0098] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 C(O)OH.

[0099] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)NHS(O) 2 N(R 10 ) 2 It is.

[0100] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0101] [ka] It is.

[0102] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0103] [ka] In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0104] [ka] and m is 2. In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0105] [ka] where m is 1.

[0106] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0107] [ka] In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0108] [ka] and q is 0. In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0109] [ka] , q is 0, and R 6 -C(O)OR 7 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0110] [ka] , q is 0, and R 6 is —C(O)OH. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0111] [ka] , q is 0, and R 6 -C(O)NHS(O) 2 N(R 10 ) 2 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4and R 4 teeth,

[0112] [ka] , q is 0, and R 6 teeth,

[0113] [ka] In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0114] [ka] , q is 0, and R 6 teeth,

[0115] [ka] It is.

[0116] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0117] In some embodiments, there is a compound of Formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, where n is 0.

[0118] In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; R 3 are each independently halogen, -OR 9 , -N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6 In some embodiments, there is provided a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; R 3 are each independently a halogen and C 1-6 In some embodiments, there are compounds of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, there are compounds of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1 and R 3 is halogen, -OH, -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1 and R 3 -OR 9 and R 9 is C 3-8 In some embodiments, there is provided a compound of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is cyclopentyl.

[0119] In some embodiments, provided herein is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof:

[0120] [ka] During the ceremony, R 1 -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R 9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl,

[0121] [ka] , or one, two, or three R 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9, -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth,

[0122] [ka] and; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C1-6 Alkyl, -C 1-6 Alkyl-R 9 , -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 , C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 is -C(O)OR 7 , -C(O)NHS(O) 2 N(R 10 ) 2 ,

[0123] [ka] and; R7 are each independently H and C 1-6 alkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 )C(O)R 12 , -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 0, 1, 2, 3, or 4.

[0124] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0125] [ka] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0126] [ka] and p is 0, 1, or 2. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0127] [ka] and p is 0. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0128] [ka] and p is 1. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0129] [ka] and p is 2. In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0130] [ka] and p is 1 or 2. In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0131] [ka] where p is 1 or 2, and R 5are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0132] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 )2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0133] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 )2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0134] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0135] [ka] where p is 1 or 2, and R 5are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0136] [ka] where p is 1 or 2, and R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0137] [ka] where p is 1 or 2, and R 5 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0138] [ka] where p is 1 or 2, and R 5 are each independently -C(O)OR 10Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0139] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0140] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 Selected from R 9 is -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0141] [ka] where p is 1 and R 5 is independently selected from:

[0142] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 11, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 5- or 6-membered heteroaryl optionally substituted with a group. 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 and R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and triazinyl. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl and pyrimidinyl. 1is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently a halogen, -C(O)OR 10 , C 1-6 Alkyl, and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl selected from pyridinyl and pyrimidinyl.

[0143] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 1-6Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6 In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0144] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6 In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0145] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is -C(O)OH.

[0146] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 C(O)OH.

[0147] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)NHS(O) 2 N(R 10 )2 It is.

[0148] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0149] [ka] It is.

[0150] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0151] [ka] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0152] [ka] and q is 0. In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0153] [ka] , q is 0, and R 6 -C(O)OR 7In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0154] [ka] , q is 0, and R 6 is —C(O)OH. In some embodiments, there is a compound of formula (I′), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0155] [ka] , q is 0, and R 6 -C(O)NHS(O) 2 N(R 10 ) 2 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0156] [ka] , q is 0, and R 6 teeth,

[0157] [ka] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4teeth,

[0158] [ka] , q is 0, and R 6 teeth,

[0159] [ka] It is.

[0160] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3 In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0161] In some embodiments, there is a compound of Formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where n is 0.

[0162] In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; R 3 are each independently halogen, -OR 9 , -N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; R 3 are each independently a halogen and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1 and R 3 is halogen, -OH, -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is C 3-8 In some embodiments, there is provided a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3-OR 9 and R 9 is cyclopentyl.

[0163] In some embodiments, provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof:

[0164] [ka] During the ceremony, R 1 is -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R 9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl,

[0165] [ka] , or one, two, or three R 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth,

[0166] [ka] and; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 is -C(O)OR 7 , -C(O)NHS(O) 2 N(R 10 ) 2 ,

[0167] [ka] and; R 7 are each independently H and C 1-6 alkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 )2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 0, 1, 2, 3, or 4.

[0168] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0169] [ka] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0170] [ka] and p is 0, 1, or 2. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0171] [ka] and p is 0. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0172] [ka] and p is 1. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 teeth,

[0173] [ka] and p is 2. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0174] [ka] and p is 1 or 2. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0175] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0176] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0177] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0178] [ka] where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2, -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0179] [ka] where p is 1 or 2, and R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0180] [ka] where p is 1 or 2, and R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 Selected from R 10are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0181] [ka] where p is 1 or 2, and R 5 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0182] [ka] where p is 1 or 2, and R 5 are each independently -C(O)OR 10 Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0183] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I''), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0184] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 Selected from R 9 is -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0185] [ka] where p is 1 and R 5 is independently selected from:

[0186] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 5- or 6-membered heteroaryl optionally substituted with a group. 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 5-membered heteroaryl optionally substituted with a group. 1 1, 2, or 3 R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a furanyl optionally substituted with a group. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group. 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and triazinyl. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl and pyrimidinyl. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is 1 is one or two R 8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is 8 are each independently a halogen, -C(O)OR 10 , C 1-6 Alkyl, and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently -C(O)OR 10In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl selected from pyridinyl and pyrimidinyl.

[0187] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6 In some embodiments, the compound is of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0188] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are independently H, C 1-6Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6 In some embodiments, the compound is of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0189] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is -C(O)OH.

[0190] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 C(O)OH.

[0191] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)NHS(O) 2 N(R 10 ) 2 It is.

[0192] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0193] [ka] It is.

[0194] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R4 teeth,

[0195] [ka] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0196] [ka] and q is 0. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0197] [ka] , q is 0, and R 6 -C(O)OR 7 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0198] [ka] , q is 0, and R 6 is —C(O)OH. In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0199] [ka] , q is 0, and R 6 -C(O)NHS(O) 2 N(R 10 ) 2 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0200] [ka] , q is 0, and R 6 teeth,

[0201] [ka] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 Ha-CH 2 R 4 and R 4 teeth,

[0202] [ka] , q is 0, and R 6 teeth,

[0203] [ka] It is.

[0204] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3 In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0205] In some embodiments, there is a compound of Formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0.

[0206] In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently halogen, -OR 9 , -N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently a halogen and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1. In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1 and R 3 is halogen, -OH, -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is C 3-8 In some embodiments, there is provided a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is cyclopentyl.

[0207] In some embodiments, provided herein is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof:

[0208] [ka] During the ceremony, R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2, -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6Alkyl-C 3-8 cycloalkyl; R 5 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; n is 0, 1, 2, or 3; and p is 0, 1, 2, 3, 4, or 5.

[0209] In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0, 1, or 2. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 0. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 2. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1 or 2. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where p is 1 or 2, and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2 and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; R 10are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2 and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2 and R 5 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 heteroaryl; R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2 and R 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2; 5 are each independently -OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2 and R 5 are each independently -C(O)OR 10 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 or 2; 5 are each independently -C(O)OR 10 Selected from R 10 are each independently H and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 teeth,

[0210] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1teeth,

[0211] [ka] where p is 1 or 2, and R 5 are each independently -OH, -OR 9 , and -C 1-6 Alkyl-C(O)OR 10 Selected from R 9 is -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 1 and R 5 is independently selected from:

[0212] In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3 In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0213] In some embodiments, there is a compound of Formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0.

[0214] In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently halogen, -OR 9 , -N(R 10 )2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently a halogen and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OH, -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1 and R 3 -OR 9 and R 9 is C 3-8In some embodiments, there is provided a compound of formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is cyclopentyl.

[0215] In some embodiments, provided herein is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof:

[0216] [ka] During the ceremony, R 1 1, 2, or 3 R 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O)2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 8 are each independently halogen, -OH, or -OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)NHS(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 )2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl; and 2-9 Heterocycloalkyl is a halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; and n is 0, 1, 2, or 3.

[0217] In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 and R is a 5-membered heteroaryl optionally substituted with a group, where the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a furanyl optionally substituted with a group. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 1, 2, or 3 R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group. 1 1, 2, or 3 R 8In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, and triazinyl. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 6-membered heteroaryl optionally substituted with a group, where the 6-membered heteroaryl is selected from pyridinyl and pyrimidinyl. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a pyridinyl optionally substituted with a group. 1 is one or two R 8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently a halogen, -C(O)OR 10 , C 1-6 Alkyl, and -C 1-6 Alkyl-C(O)OR 10 In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 8 are each independently -C(O)OR 10 In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 5-membered heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl. In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is an unsubstituted 6-membered heteroaryl selected from pyridinyl and pyrimidinyl.

[0218] In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3 In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0219] In some embodiments, there is a compound of Formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0.

[0220] In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9, -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently halogen, -OR 9 , -N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently a halogen and C 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OH, -OR9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is C 3-8 In some embodiments, there is provided a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is cyclopentyl.

[0221] In some embodiments, provided herein is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof:

[0222] [ka] During the ceremony, R 1 -C(O)N(R 10 )2 and; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; and n is 0, 1, 2, or 3.

[0223] In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR12 In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6 In some embodiments, the compound is of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -C(O)N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0224] In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3 In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H. In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0225] In some embodiments, there is a compound of Formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0.

[0226] In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; R 3 are each independently halogen, -OR 9 , -N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently a halogen and C 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OH, -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1 and R 3 -OR 9 and R 9 is C 3-8 In some embodiments, there is provided a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3-OR 9 and R 9 is cyclopentyl.

[0227] In some embodiments, provided herein is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof:

[0228] [ka] During the ceremony, R 1 -N(R 10 ) 2 and; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -OC 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl; R 3 are each independently halogen, -CN, -OH, -OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2, -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9Heteroaryl is C 1-6 Alkyl, -OR11, -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)R 12 , and -C(O)OR 12 optionally substituted with one or two groups independently selected from R 10 are independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 or optionally substituted with one or two groups independently selected from 10 , and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl; R 12 are independently H and C 1-6 alkyl; and n is 0, 1, 2, or 3.

[0229] In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are independently H, C 1-6Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, Phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are independently H, C 1-6 Alkyl, C 3-8 Cycloalkyl, phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, and C 2-9 Heteroaryl is independently selected from halogen, C 1-6 Alkyl, -N(R 11 ) 2 , and -C(O)OR 12 In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 are each independently H, and -C(O)OR 12 C optionally substituted with 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 10 each independently represents H, and C optionally substituted with -C(O)OH 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10) 2 and two R 10 , and the nitrogen atom to which they are attached together form C 1-6 In some embodiments, the compound is of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is an alkyl, oxo, or -C(O)OH group. 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 5-membered heterocycloalkyl ring substituted with -C(O)OH. In some embodiments, there are compounds of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 -N(R 10 ) 2 and two R 10 and the nitrogen atom to which they are attached, taken together, form a 6-membered heterocycloalkyl ring substituted with -C(O)OH.

[0230] In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 is H, -OH, -N(R 10 ) 2 , or -OC 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 Ha-OC 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 HA-OCH 2 CH 3 In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2is H. In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein R 2 -N(R 10 ) 2 It is.

[0231] In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0.

[0232] In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3. In some embodiments, there is a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, where n is 1, 2, or 3, and R 3 are each independently halogen, -CN, or -OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N(R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 1-6 Haloalkyl, C3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently halogen, -OR 9 , -N(R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , and C 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1, 2, or 3; and R 3 are each independently a halogen and C 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1. In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OH, -OR 9 , -N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 is halogen, -OR 9 , and C 1-6In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is C 3-8 In some embodiments, there is provided a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1 and R 3 -OR 9 and R 9 is cyclopentyl.

[0233] In some embodiments,

[0234] [ka]

[0235] [ka]

[0236] [ka]

[0237] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0238] In some embodiments,

[0239] [ka]

[0240] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0241] In some embodiments,

[0242] [ka]

[0243] [ka]

[0244] [ka]

[0245] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0246] In some embodiments,

[0247] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0248] In some embodiments,

[0249] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0250] In some embodiments,

[0251] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0252] Any combination of the above groups of the various variables is contemplated herein. Throughout the specification, groups and substituents thereof can be selected by one of skill in the art to provide stable moieties and compounds.

[0253] In some embodiments, a therapeutic agent (e.g., a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id)) is present in the pharmaceutical composition as a pharma- ceutically acceptable salt. In some embodiments, the compounds described above are suitable for any of the methods or compositions described herein.

[0254] Further forms of the compounds disclosed herein Isomers Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, and their corresponding mixtures. In some circumstances, the compounds exist as tautomers. The compounds described herein include all tautomers possible in the formulas described herein. In some circumstances, the compounds described herein have one or more chiral centers, and each center exists in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, and their corresponding mixtures. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers derived from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic separation of a racemic mixture. In some embodiments, the compounds described herein are prepared as individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomer. In some embodiments, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by taking advantage of these differences. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, separation / resolution techniques based on solubility differences. In some embodiments, the optically pure enantiomers are recovered along with the resolving agent by any practical means that do not result in racemization.

[0255] labeled compound In some embodiments, the compounds described herein are present in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds, which are identical to the compounds listed herein except that one or more atoms are replaced with atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that may be incorporated into the compounds described herein include, respectively, isotopically labeled compounds, which may be identical to the compounds listed herein except that one or more atoms are replaced with atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, and 36 Included are isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, such as Cl. Compounds described herein, and pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, that contain the aforementioned isotopes and / or other isotopes of other atoms, are within the scope of the present invention. Certain isotopically labeled compounds, e.g., 3 H and 14 Compounds into which a radioactive isotope, such as C, is incorporated are useful in drug and / or substrate tissue distribution assays. 3 H), and carbon-14 (i.e. 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Additionally, deuterium (i.e., 2Substitution with heavy isotopes, such as H, can confer certain therapeutic advantages due to improved metabolic stability, such as increased in vivo half-life or reduced dosage requirements. In some embodiments, isotopically labeled compounds, or pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, are prepared by any suitable method.

[0256] In some embodiments, the compounds described herein are labeled by other means, including but not limited to, a chromophore or fluorescent moiety, a bioluminescent label, or a chemiluminescent label.

[0257] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharma- ceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharma- ceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharma- ceutically acceptable salts as pharmaceutical compositions.

[0258] In some embodiments, the compounds described herein have acidic or basic groups and thus react with any of a number of inorganic or organic bases, as well as inorganic and organic acids, to form pharma- ceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting the purified compounds in free form with the appropriate acid or base and isolating the salt thus formed.

[0259] solvate In some embodiments, the compounds described herein exist as solvates. In some embodiments, there are methods of treating diseases by administering such solvates. Methods of treating diseases by administering such solvates as pharmaceutical compositions are further described herein.

[0260] Solvates contain stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments are formed during the process of crystallization with pharma- ceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, and alcohols are formed when the solvent is alcohol. Solvates of the compounds described herein are suitably prepared or formed during the process described herein. By way of example only, hydrates of the compounds described herein are suitably prepared by recrystallization from aqueous / organic solvent mixtures using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or MeOH. Furthermore, the compounds provided herein exist in solvated and unsolvated forms. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0261] Compound synthesis In some embodiments, the synthesis of the compounds described herein is accomplished using means described in the chemical literature, using methods described herein, or by a combination thereof. In addition, solvents, temperatures, and other reaction conditions indicated herein may be varied.

[0262] In other embodiments, the starting materials and reagents used in the synthesis of the compounds described herein are synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fischer Scientific (Fischer Chemicals), and Acros Organics.

[0263] In further embodiments, the compounds described herein, and other related compounds having various substituents, can be prepared using techniques and materials described herein and in other publications such as, for example, Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4 th Ed.,(Wiley 1992);Carey and Sundberg,Advanced Organic Chemistry 4 th Ed.,Vols.A and B(Plenum 2000,2001), and Green and Wuts,Protective Groups in Organic Synthesis 3 rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). The general method for the preparation of the compounds disclosed herein may be derived from reactions, which may be modified using appropriate reagents and conditions to introduce various moieties found in the methods provided herein. The following synthetic methods may be used as a guide.

[0264] Use of Protecting Groups In the reactions described, reactive functional groups, such as hydroxy, amino, imino, thio, or carboxy groups, may need to be protected to avoid undesired participation in the reaction if these groups are desired in the final product. Protecting groups are used to block some or all of the reactive moieties and to prevent such groups from participating in chemical reactions until the protecting group is removed. It is preferred that each protecting group is removable by a different means. Protecting groups that are cleaved under completely different reaction conditions meet the requirement of differential removal.

[0265] Protecting groups can be removed by acid, base, reducing conditions (e.g., hydrogenolysis, etc.), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, and t-butyldimethylsilyl are acid labile and may be used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups (removable by hydrogenolysis) and Fmoc groups (base labile). Carboxylic acid and hydroxy reactive moieties can be blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butyl carbamate, or carbamates that are both acid and base stable but removable by hydrolysis.

[0266] Carboxylic acid and hydroxy reactive moieties may also be blocked with hydrolytically removable protecting groups such as benzyl groups, while amine groups capable of hydrogen bonding with acids may be blocked with base labile groups such as Fmoc. Carboxylic acid reactive moieties may be protected by conversion to simple ester compounds as exemplified herein, including conversion to alkyl esters, or may be blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while coexisting amino groups may be blocked with fluoride labile silyl carbamates.

[0267] Allyl blocking groups are useful in the presence of acid and base protecting groups because the former are stable and can be subsequently removed by metal or pi-acid catalysis. For example, allyl-blocked carboxylic acids can be reacted with Pd 0 It can be deprotected by a catalytic reaction. However, another form of protecting group is a resin to which a compound or intermediate can be attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group can react.

[0268] Typically, the blocking / protecting group is

[0269] [ka] may be selected from:

[0270] Detailed descriptions of other protecting groups and applicable techniques for their creation and removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for their disclosure.

[0271] Treatment and prevention In some embodiments, there are methods of treating inflammatory bowel disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there are methods of treating inflammatory bowel disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is selected from Crohn's disease, ulcerative colitis, and perianal Crohn's disease. In some embodiments, there is a method of treating inflammatory bowel disease in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein said inflammatory bowel disease is Crohn's disease. In some embodiments, there is a method of treating inflammatory bowel disease in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein said inflammatory bowel disease is ulcerative colitis. Optionally, the ulcerative colitis is a severe form of ulcerative colitis. Optionally, the severe form of ulcerative colitis is medically refractory ulcerative colitis. In some embodiments, there is a method of treating inflammatory bowel disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof, wherein the inflammatory bowel disease is perianal Crohn's disease.

[0272] Pharmaceutical Compositions and Methods of Administration In some embodiments, the compounds described herein are administered as pure chemicals. In other embodiments, the compounds described herein are combined with a pharma- ceutically suitable or acceptable carrier (also referred to herein as a pharma- ceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on the selected route of administration and standard pharmaceutical practice, e.g., as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[0273] Thus, provided herein are pharmaceutical compositions comprising at least one compound described herein, or a pharma- ceutically acceptable salt thereof, together with one or more pharma- ceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., subject) of the composition.

[0274] In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of Formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of Formula (I), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of Formula (I'), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of Formula (I''), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of Formula (Ia), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of Formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof.

[0275] Another embodiment provides a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutical carrier and a compound of formula (I''), or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutical carrier and a compound of formula (Ia), or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (Ib), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (Ic), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (Id), or a pharma- ceutically acceptable salt or solvate thereof.

[0276] In certain embodiments, the compounds described herein are substantially pure in that they contain less than about 5%, alternatively less than about 1%, alternatively less than about 0.1%, of other small organic molecules, e.g., contaminating intermediates or by-products produced during one or more of the steps of a synthetic method.

[0277] These formulations include those suitable for oral, topical, buccal, parenteral (eg, subcutaneous, intramuscular, intradermal, or intravenous) or aerosol administration.

[0278] Exemplary pharmaceutical compositions are used in the form of pharmaceutical preparations, e.g., solid, semi-solid, or liquid forms, which contain one or more of the disclosed compounds as active ingredients in admixture with organic or inorganic carriers or excipients suitable for external, enteral, or parenteral use. In some embodiments, the active ingredient is, for example, mixed with a normally non-toxic pharma- ceutically acceptable carrier and made into tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and other forms suitable for use. The active subject compound is included in the pharmaceutical composition in an amount sufficient to exert the desired effect on the disease process or condition.

[0279] In some embodiments for preparing solid compositions such as tablets, the primary active ingredient is mixed with a pharmaceutical carrier, such as conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, such as water, to form a solid preformulation composition containing a homogenous mixture of the disclosed compound or a non-toxic, pharma-ceutically acceptable salt thereof. When such a preformulation composition is referred to as homogenous, it is meant that the active ingredient is evenly dispersed throughout the composition such that the composition may be readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules.

[0280] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the subject compositions are mixed with one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or glycerides. and / or acacia;(3) humectants such as glycerol;(4) disintegrating agents such as crospovidone, croscarmellose sodium, sodium starch glycolate, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate;(5) solution retarding agents such as paraffin;(6) absorption accelerators such as quaternary ammonium compounds;(7) wetting agents such as, for example, docusate sodium, cetyl alcohol, and glycerol monostearate;(8) absorbents such as kaolin and bentonite clay;(9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and(10) coloring agents. In the case of capsules, tablets, and pills, in some embodiments, the composition comprises a buffering agent. In some embodiments, solid compositions of a similar type are also employed as fillers in soft- or hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.

[0281] In some embodiments, tablets are made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents, or dispersants. In some embodiments, molded tablets are made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. In some embodiments, tablets and other solid dosage forms such as dragees, capsules, pills, and granules are obtained or prepared with coatings and shells, such as enteric coatings and other coatings.

[0282] Pharmaceutical compositions suitable for parenteral administration comprise the subject composition in combination with one or more pharma- ceutically acceptable sterile, isotonic, aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders to be reconstituted immediately prior to use into sterile injectable solutions or dispersions, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0283] Examples of suitable water-soluble and non-water-soluble carriers used in pharmaceutical compositions include water, ethanol, polyol (glycerin, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oil such as olive oil, and injectable organic acid ester such as ethyl oleate and cyclodextrin.Proper fluidity is maintained, for example, by using coating materials such as lecithin, by maintaining the required particle size in the case of dispersion, and by using surfactants.

[0284] Compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid dosage forms for oral administration include pharma-ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the subject compositions, in some embodiments, liquid dosage forms include inert diluents, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, cyclodextrins, and mixtures thereof.

[0285] In some embodiments, suspensions contain, in addition to the subject compositions, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, and tragacanth, and mixtures thereof.

[0286] In some embodiments, powders and sprays contain, in addition to the subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these substances. In some embodiments, sprays further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, e.g., butane and propane.

[0287] The compositions and compounds disclosed herein are alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation, or solid microparticles containing the compound. In some embodiments, a non-aqueous (e.g., fluorocarbon propellant) suspension is used. In some embodiments, a sonic nebulizer is used to minimize exposing the drug to shear that would result in degradation of the compound contained in the subject composition. Typically, aqueous aerosols are made by formulating an aqueous solution or suspension of the subject composition together with conventional pharma- ceutically acceptable carriers and stabilizers. Carriers and stabilizers vary according to the requirements of the particular subject composition, but typically include non-ionic surfactants (Tween, Pluronic, or polyethylene glycol), innocuous proteins such as serum albumin, sorbitan esters, amino acids such as oleic acid, lecithin, glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are generally prepared from isotonic solutions.

[0288] In some embodiments, the compositions and compounds described herein are administered to a subject in a biologically compatible form suitable for topical administration. Topical administration can be presented in the form of an aerosol, semi-solid pharmaceutical composition, powder, or solution. The term "semi-solid composition" refers to an ointment, cream, salve, jelly, or other pharmaceutical composition having a substantially similar viscosity suitable for application to the skin. Examples of semi-solid compositions are described in Chapter 17 of The Theory and Practice of Industrial Pharmacy, Lachman, Lieberman and Kanig, Published by Lea and Febiger (1970), published by Mack Publishing Company, and Chapter 67 of Remington's Pharmaceutical Sciences, 15th Edition (1975).

[0289] Transdermal or skin patches are another method for transdermal delivery of the therapeutic or pharmaceutical compositions described herein. Patches can provide absorption enhancers such as DMSO to increase the absorption of the compound. Patches can also include those that control the rate of drug delivery to the skin.

[0290] Ointments, pastes, creams, and gels may also contain excipients such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, and talc, or mixtures thereof. Powders and sprays may also contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, or mixtures of these materials. The solution of nanocrystalline antimicrobial metals can be converted into an aerosol or spray by any of the known means routinely used to make aerosol pharmaceuticals. In general, such methods include pressurizing or providing a means to pressurize a container of the solution, usually with an inert carrier gas, and forcing the pressurized gas through a small opening. The spray may further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0291] The dosage of a composition comprising at least one inhibitory compound as described herein will vary depending on the patient's (e.g., human) condition, i.e., stage of the disease, general health, age, and other factors.

[0292] The pharmaceutical composition is administered in a manner appropriate for the disease to be treated (or prevented). The appropriate dose and the appropriate time and frequency of administration are determined by factors such as the condition of the patient, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition in an amount sufficient to provide a therapeutic and / or prophylactic benefit (e.g., improved clinical outcome, e.g., frequent complete or partial remission, or longer disease-free and / or overall survival, or reduced severity of symptoms, etc.). Optimal doses are generally determined using experimental models and / or clinical trials. In some embodiments, optimal doses depend on the patient's body type, weight, or blood volume.

[0293] Oral dosages typically range from about 1.0 mg to about 1000 mg, one to four or more times per day.

[0294] Dose administration may be repeated depending on the pharmacokinetic parameters of the dosage formulation and the route of administration used.

[0295] It is particularly advantageous to formulate compositions in dosage unit forms for ease of administration and uniformity of dosage. Dosage unit forms as used herein refer to physically discrete units suitable as unitary dosages for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier. The specifications for dosage unit forms are determined by and directly depend on (a) the intrinsic properties of the compound of formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id) and the particular therapeutic effect to be achieved, and (b) the inherent limitations in the technology of compounding such active compounds for the treatment of individual hypersensitivity. The specific dosage can be easily calculated by those skilled in the art according to, for example, the approximate body weight or body surface area of ​​the patient, or the volume of the body space to be occupied. The dosage is further calculated depending on the particular route of administration selected. The exact dosage is determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by the practitioner taking into consideration the relevant circumstances, including the disease being treated, the choice of composition to be administered, the age, weight, and response of the particular patient, the severity of the patient's symptoms, and the selected route of administration.

[0296] The toxicity and therapeutic efficacy of the compounds of formula (I), (I'), (I''), (Ia), (Ib), (Ic), or (Id) can be determined, for example, by LD 50 (a dose lethal to 50% of the population) and ED 50 The dose ratio between toxic and therapeutic effects is the therapeutic index, which is the ratio LD 50 / ED 50 It can be expressed as: EXAMPLES

[0297] The following examples are provided for illustrative purposes and are not intended to limit the scope of the claims provided herein.

[0298] As used above, and throughout the description of the present invention, unless otherwise specified, the following abbreviations shall be understood to have the following meanings: ACN or MeCN Acetonitrile AcOH Acetic acid AlMe 3 Trimethylaluminum Bn Benzyl BOC or Boc t-Butyl Carbamate CDI 1,1'-Carbonyldiimidazole Cy 3 P BF 4 Tricyclohexylphosphonium tetrafluoroborate DCE Dichloroethane DCM Dichloromethane DDQ 2,3-Dichloro-5,6-dicyano-p-benzoquinone DIPEA or DIEA Diisopropylethylamine DMAP 4-(N,N-dimethylamino)pyridine DMF Dimethylformamide DMA N,N-Dimethylacetamide DMSO Dimethyl sulfoxide equiv equivalent Et Ethyl EtOH Ethanol EA or EtOAc Ethyl acetate HPLC High Performance Liquid Chromatography LAH Lithium aluminum hydride Me Methyl MeOH Methanol MS mass spectrometry NMM N-Methylmorpholine NMR nuclear magnetic resonance Pd(dppf)Cl 2 [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd(DTBPF)Cl 2[1,1'-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) Pd(OAc) 2 Palladium(II) Acetate PMB para-methoxybenzyl TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran

[0299] Example 1: Synthesis of 5-(3-ethoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 101)

[0300] [ka]

[0301] Step 1: 4-Bromo-2-hydroxybenzonitrile (3.00 g, 15.2 mmol, 1.00 equiv) and K in DMF (30.0 mL) 2 CO 3 To a stirred solution of (4.19 g, 30.3 mmol, 2.00 equiv) was added ethyl iodide (3.07 g, 19.7 mmol, 1.30 equiv) at room temperature. The resulting mixture was stirred overnight. The resulting mixture was diluted with water (100 mL). The precipitated solid was collected by filtration and washed with water (2x20 mL). The resulting solid was dried under an infrared lamp. This gave 4-bromo-2-ethoxybenzonitrile (3 g, 88%) as an off-white solid.

[0302] Step 2: NH in toluene (20.0 mL) 4 To a stirred mixture of AlMeCl (2.37 g, 44.2 mmol, 4.00 equiv.) was added 3 (22.1 mL, 44.2 mmol, 4.00 equiv.) 2Dropwise addition at room temperature under atmospheric pressure. The resulting mixture was stirred at room temperature for 30 min. To the above mixture was added 4-bromo-2-ethoxybenzonitrile (2.50 g, 11.1 mmol, 1.00 equiv). The resulting mixture was stirred at 110° C. for an additional 16 h. The mixture was cooled to 0° C. The reaction was quenched by dropwise addition of methanol (50 mL). The solid was filtered and the filter cake was washed with methanol (3×30 mL) and DCM (3×30 mL). The filtrate was concentrated under reduced pressure until a small amount of solvent remained. The residue was diluted with EA (30 mL) and the precipitated solid was collected by filtration and washed with EA (2×20 mL). The resulting solid was dried under infrared lamp. This gave 4-bromo-2-ethoxybenzenecarboximidamide hydrochloride (3 g, 97%) as a white solid. LCMS (ESI)=243.1, 245.1 [M+H] + .

[0303] Step 3: To a stirred solution of MeOH (30 mL), Na (0.99 g, 42.9 mmol, 4.00 equiv.) was added 2 The mixture was added in portions at room temperature under atmosphere. The resulting mixture was stirred until the solids were completely dissolved at room temperature. To the above mixture, 4-bromo-2-ethoxybenzenecarboximidamide hydrochloride (3.00 g, 10.7 mmol, 1.00 equiv.) and (E)-(ethyl cyano(hydroxyimino)formate) (3.05 g, 21.5 mmol, 2.00 equiv.) were added. The resulting mixture was refluxed overnight. The mixture was cooled to room temperature. The reaction was quenched by the addition of water (100 mL). The mixture was acidified to pH 5.0 with AcOH. The precipitated solid was collected by filtration and washed with water (3x20 mL). The resulting solid was dried using infrared light. This gave 6-amino-2-(4-bromo-2-ethoxyphenyl)-5-nitroso-3H-pyrimidin-4-one (3 g, 82%) as a green solid. LCMS(ESI)=338.8, 340.8[M+H] + .

[0304] Step 4: To a stirred solution of 6-amino-2-(4-bromo-2-ethoxyphenyl)-5-nitroso-3H-pyrimidin-4-one (2.00 g, 5.90 mmol, 1.00 equiv) in water (20.0 mL) and TEA (4.00 mL) was added Na 2 S 2 O 4 (3.08 g, 17.7 mmol, 3.00 equiv) was added at room temperature. The resulting mixture was stirred at room temperature for 30 min. The resulting mixture was diluted with water (20 mL). The mixture was acidified to pH 5.0 with AcOH. The precipitated solid was collected by filtration and washed with water (2x10 mL). The resulting solid was dried using infrared light. This gave 5,6-diamino-2-(4-bromo-2-ethoxyphenyl)-3H-pyrimidin-4-one (1 g, 52%) as a green solid. LCMS (ESI) = 325.1, 327.1 [M+H] + .

[0305] Step 5: To a stirred solution of 5,6-diamino-2-(4-bromo-2-ethoxyphenyl)-3H-pyrimidin-4-one in HCl (6M) (10.0 mL) was added sodium nitrite (0.42 g, 6.15 mmol, 2.00 equiv) in portions at 0° C. The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was diluted with water (30 mL). The precipitated solid was collected by filtration and washed with water (2×10 mL). The crude product was purified by preparative HPLC to give 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (600 mg, 58%) as a white solid. LCMS (ESI)=336.0, 337.9 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.26(s,1H),7.63(d,J=8.2Hz,1H),7.41(d,J=1.7Hz,1H),7.30(dd,J=8.3,1.7Hz,1H),4.17(q,J=6.9Hz,2H),1.32(t,J=6.9Hz,3H).

[0306] Step 6: Into an 8 mL sealed tube purged and maintained with an inert atmosphere of nitrogen, add 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (30 mg, 1 equiv.), phenylboronic acid (21.7 mg, 2 equiv.), dioxane (0.5 mL), H 2 O (0.1 mL), K 2 CO 3 (36.9 mg, 3 equivalents), Pd(dppf)Cl 2 (6.5 mg, 0.1 equiv.). The resulting solution was stirred in an oil bath at 100° C. for 2 hours. The solid was filtered off. The resulting mixture was concentrated under vacuum. The crude product was purified by preparative HPLC to give 5-(3-ethoxy-[1,1′-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 101) (12 mg, 40%) as a pale yellow solid. LCMS (ESI)=334[M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.24(s,1H),7.87(d,J=8.0Hz,1H),7.79(d,J=7.1Hz,2H),7.52(t,J=7. 3Hz,2H),7.44(q,J=7.5Hz,3H),4.31(q,J=6.9Hz,2H),1.40(t,J=6.9Hz,3H)

[0307] Example 2: Synthesis of 5-(2-ethoxy-4-(pyridin-3-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 102)

[0308] [ka]

[0309] 5-(2-ethoxy-4-(pyridin-3-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 102) was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and pyridin-3-ylboronic acid using the procedure of Example 1, step 6. LCMS (ESI) = 335.1 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.34(s,1H),9.23(d,J=1.8Hz,1H),8.81(dd,J=5.2,1.3Hz,1H),8.64(d,J=8.0Hz,1H),7.88(dd,J= 8.0,3.6Hz,2H),7.61(s,1H),7.55(dd,J=8.0,1.5Hz,1H),4.32(q,J=7.0Hz,2H),1.39(t,J=6.9Hz,3H).

[0310] Example 3: Synthesis of 5-(2-ethoxy-4-(pyrimidin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 103)

[0311] [ka]

[0312] 5-(2-ethoxy-4-(pyrimidin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and 2-(tributylstannyl)pyrimidine using the procedure of Example 1, step 6. LCMS (ESI)=336.1 [M+H] + .

[0313] Example 4: Synthesis of 5-(2-ethoxy-4-(pyridin-4-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 104)

[0314] [ka]

[0315] 5-(2-ethoxy-4-(pyridin-4-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and pyridin-4-ylboronic acid using the procedure in Example 1, step 6. LCMS (ESI) = 335.1 [M + H] + .

[0316] Example 5: Synthesis of 5-(2-ethoxy-4-(pyridin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 105)

[0317] [ka]

[0318] 5-(2-ethoxy-4-(pyridin-2-yl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one and 2-(tributylstannyl)pyridine using the procedure in Example 1, step 6. LCMS (ESI) = 335.1 [M+H] + .

[0319] Example 6: Synthesis of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (Compound 106)

[0320] [ka]

[0321] Step 1: To a stirred solution of 1-(azidomethyl)-4-methoxybenzene (5.00 g, 30.6 mmol, 1.00 equiv) and cyanoacetamide (2.58 g, 30.6 mmol, 1.00 equiv) in EtOH (50.0 mL) was added N 2 EtONa (6.26 g, 91.9 mmol, 3.00 equiv) was added at room temperature under atmospheric pressure. The resulting mixture was then cooled to 5° C. 2 The mixture was stirred at 78° C. under atmospheric pressure for 3 h. The mixture was cooled to room temperature. The precipitated solid was collected by filtration and washed with EtOH (2×10 mL). The resulting solid was dried under an infrared lamp. This gave 5-amino-1-[(4-methoxyphenyl)methyl]-1,2,3-triazole-4-carboxamide (3 g, 40%) as a grey solid.

[0322] Step 2: 4-Bromo-2-hydroxybenzaldehyde (2.00 g, 9.949 mmol, 1.00 equiv) in DMF (20.0 mL) and K 2 CO 3 To a stirred solution of (2.75 g, 19.9 mmol, 2.00 equiv) was added ethyl iodide (1.86 g, 11.9 mmol, 1.20 equiv) at room temperature. The resulting mixture was stirred at room temperature overnight. The resulting mixture was diluted with water (100 mL). The precipitated solid was collected by filtration and washed with water (2x20 mL). The resulting solid was dried under an infrared lamp. This gave 4-bromo-2-ethoxybenzenealdehyde (1.9 g, 83%) as a white solid.

[0323] Step 3: To a stirred solution of 5-amino-1-[(4-methoxyphenyl)methyl]-1,2,3-triazole-4-carboxamide (1.50 g, 6.07 mmol, 1.00 equiv) and 4-bromo-2-ethoxybenzaldehyde (2.08 g, 9.10 mmol, 1.50 equiv) in AcOH (20.0 mL) was added DDQ (2.75 g, 12.1 mmol, 2.00 equiv) at room temperature. The resulting mixture was stirred at 80° C. for 24 h. The mixture was cooled to room temperature. The resulting mixture was diluted with water (50 mL). The precipitated solid was collected by filtration and washed with water (2×10 mL). The residue was redissolved in aqueous sodium bicarbonate (50 mL). The precipitated solid was collected by filtration and washed with aqueous sodium bicarbonate (2×10 mL) and water (2×10 mL). The resulting solid was dried under an infrared lamp. This gave 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 106-A) (1.5 g, crude) as a grey solid. The crude product (30 mg) was purified by preparative HPLC to give 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (7 mg) as a white solid. LCMS (ESI) = 456 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.44(s,1H),7.68(d,J=8.3Hz,1H),7.43(d,J=1.5Hz,1H),7.35(d,J=8.4Hz,3H),6.92 (d,J=8.7Hz,2H),5.69(s,2H),4.18(q,J=6.9Hz,2H),3.73(s,3H),1.32(t,J=6.9Hz,3H).

[0324] Step 4: Dioxane / H 25-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (100 mg, 0.219 mmol, 1.00 equiv.), 2-(methoxycarbonyl)phenylboronic acid (78.9 mg, 0.438 mmol, 2.00 equiv.), and K 2 CO 3 To a stirred solution of (90.86 mg, 0.657 mmol, 3.00 equiv.) Pd(dppf)Cl 2 CH 2 Cl 2 (17.9 mg, 0.022 mmol, 0.10 equiv.) 2 The mixture was added at room temperature under atmospheric pressure. The resulting mixture was stirred at 100° C. overnight. The mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with water (2 mL). The precipitated solid was collected by filtration and washed with water (2×2 mL). The resulting solid was dried under an infrared lamp. This gave methyl 3′-ethoxy-4′-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1′-biphenyl]-2-carboxylate (100 mg, 89%) as a grey solid.

[0325] Step 5: A solution of methyl 3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (100 mg, 0.195 mmol, 1 equiv.) in 2,2,2-trifluoroacetaldehyde (1 mL) was stirred at 80° C. for 2 h. The mixture was cooled to room temperature. The resulting mixture was diluted with water (5 mL). The precipitated solid was collected by filtration and washed with water (2×1 mL). The resulting solid was dried by infrared light. This gave methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (90 mg, crude) as a grey solid. The crude product (20 mg) was purified by preparative HPLC to give methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (5 mg, 6%) as a white solid. LCMS (ESI) = 392.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.03(s,1H),8.14(s,1H),7.85(d,J=7.9Hz,1H),7.79(d,J=7.7Hz,1H),7.68(t,J=7.6Hz,1H),7.55(t,J =7.4Hz,2H),7.09(s,1H),7.02(d,J=8.0Hz,1H),4.20(q,J=6.7Hz,2H),3.66(s,3H),1.38(t,J=6.9Hz,3H).

[0326] Example 7: Synthesis of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate (Compound 107)

[0327] [ka]

[0328] Methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate was prepared using the procedure of Example 6, steps 4 and 5, except that (3-(methoxycarbonyl)phenyl)boronic acid was used in step 4. LCMS (ESI) = 392.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.22(s,1H),8.28(s,1H),8.06(dd,J=17.6,7.8Hz,2H),7.90(d,J=7.9Hz,1H),7.69(t,J=7 .8Hz,1H),7.52-7.41(m,1.8Hz,2H),4.32(q,J=6.9Hz,2H),3.92(s,3H),1.40(t,J=6.9Hz,3H).

[0329] Example 8: Synthesis of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate (Compound 108)

[0330] [ka]

[0331] Methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate was prepared using the procedure of Example 6, steps 4 and 5, except that (4-(methoxycarbonyl)phenyl)boronic acid was used in step 4. LCMS (ESI) = 392.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ12.26(s,1H),8.09(d,J=8.5Hz,2H),7.96(d,J=8.5Hz,2H),7.89(d,J=7.9Hz,1 H),7.56-7.45(m,2H),4.32(q,J=7.1Hz,2H),3.90(s,3H),1.40(t,J=6.9Hz,3H).

[0332] Example 9: Synthesis of 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylic acid (Compound 109)

[0333] [ka]

[0334] MeOH / H 2 To a stirred solution of methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylate (70.0 mg, 0.179 mmol, 1.00 equiv) in 2H2O (2 / 0.4 mL) was added NaOH (35.8 mg, 0.894 mmol, 5.00 equiv) dropwise at room temperature. The resulting mixture was stirred at 40° C. overnight. The resulting mixture was diluted with water (10 mL). The aqueous layer was extracted with EA (2x5 mL). The mixture was acidified to pH 3-4 with concentrated HCl. The resulting mixture was extracted with EA (3x5 mL). The combined organic layers were washed with brine (1x10 mL) and washed with anhydrous Na 2 SO 4 The mixture was dried over ice. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-carboxylic acid (compound 109) (20.5 mg, 30%) as a white solid. LCMS (ESI) = 378.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6 )δ12.23(s,1H),7.90-7.73(m,J=13.7,4.6Hz,2H),7.69-7.57(m,J=7.5,1.4Hz,1H),7.57-7.42(m,2 H),7.15(d,J=1.2Hz,1H),7.07(dd,J=8.0,1.4Hz,1H),4.21(q,J=6.9Hz,2H),1.37(t,J=6.9Hz,3H).

[0335] Example 10: Synthesis of 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 110)

[0336] [ka]

[0337] 3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (compound 110) was prepared from compound 107 using the procedure of example 9. LCMS (ESI) = 378.1 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.20(s,1H),8.27(s,1H),8.09-7.97(m,2H),7.90(d,J=7.9Hz,1H),7.66(t ,J=7.8Hz,1H),7.52-7.40(m,2H),4.33(q,J=6.9Hz,2H),1.40(t,J=6.9Hz,3H).

[0338] Example 11: Synthesis of 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 111 palladium(II) acetate)

[0339] [ka]

[0340] 3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (compound 111) was prepared from compound 108 using the procedure of example 9. LCMS (ESI) = 378.1 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.04(s,1H),8.06(d,J=8.4Hz,2H),7.99-7.87(m,3H),7.56-7.43(m,2H),4.32(q,J=6.8Hz,2H),1.40(t,J=6.9Hz,3H).

[0341] Example 12: Synthesis of methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinate (Compound 112)

[0342] [ka]

[0343] Methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinate (compound 112) was prepared using the procedures of example 6, steps 4 and 5, except that (5-(methoxycarbonyl)pyridin-3-yl)boronic acid was used in step 4. LCMS (ESI)=393.2 [M+H] + .

[0344] Example 13: Synthesis of 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid (compound 113)

[0345] [ka]

[0346] 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid (compound 113) was prepared from compound 112 using the procedure of Example 9.

[0347] Example 14: Synthesis of methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetate (Compound 114)

[0348] [ka]

[0349] Methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetate (compound 114) was prepared using the procedure of example 6, steps 4 and 5, except that (4-(2-methoxy-2-oxoethyl)phenyl)boronic acid was used in step 4. LCMS (ESI) = 406.2 [M+H] + .

[0350] Example 15: Synthesis of 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 115)

[0351] [ka]

[0352] 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid (compound 115) was prepared from compound 114 using the procedure of example 9. LCMS (ESI) = 392.1 [M+H] + .

[0353] Example 16: Synthesis of methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylate (Compound 116)

[0354] [ka]

[0355] Methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylate (compound 116) was prepared using the procedure of example 6, steps 4 and 5, except that methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylate was used in step 4. LCMS (ESI)=398.1 [M+H] + .

[0356] Example 17: Synthesis of 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylic acid (Compound 117)

[0357] [ka]

[0358] 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)thiophene-2-carboxylic acid (compound 117) was prepared from compound 116 using the procedure of example 9. LCMS (ESI) = 384.1 [M + H] + .

[0359] Example 18: Synthesis of methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetate (Compound 118)

[0360] [ka]

[0361] Methyl 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetate (compound 118) was prepared using the procedure of example 6, steps 4 and 5, except that (2-(2-methoxy-2-oxoethyl)phenyl)boronic acid was used in step 4. LCMS (ESI) = 406.2 [M+H] + .

[0362] Example 19: Synthesis of 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetic acid (Compound 119)

[0363] [ka]

[0364] 2-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-2-yl)acetic acid (compound 119) was prepared from compound 118 using the procedure of example 9. LCMS (ESI) = 392.2 [M + H] + .

[0365] Example 20: Synthesis of ethyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (Compound 120)

[0366] [ka]

[0367] Ethyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (compound 120) was prepared using the procedure of Example 6, steps 4 and 5, except that ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate was used in step 4. LCMS (ESI) = 436.2 [M+H] + .

[0368] Example 21: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 121)

[0369] [ka]

[0370] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (compound 121) was prepared from compound 120 using the procedure of example 9. LCMS (ESI) = 408.2 [M+H] + .

[0371] Example 22: Synthesis of methyl 5-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate (Compound 122)

[0372] [ka]

[0373] Methyl 5-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate was prepared using the procedure of Example 6, steps 4 and 5, except that (3-amino-5-(methoxycarbonyl)phenyl)boronic acid hydrochloride was used in step 4. LCMS (ESI) = 407.2 [M+H] + .

[0374] Example 23: Synthesis of 5-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 123)

[0375] [ka]

[0376] 5-Amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (compound 123) was prepared from compound 122 using the procedure of example 9. LCMS (ESI) = 393.1 [M + H] + .

[0377] Example 24: Synthesis of methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinate (Compound 124)

[0378] [ka]

[0379] Methyl 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinate (compound 124) was prepared using the procedure of example 6, steps 4 and 5, except that (6-(methoxycarbonyl)pyridin-3-yl)boronic acid was used in step 4. LCMS (ESI)=393.1 [M+H] + .

[0380] Example 25: Synthesis of 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid (compound 125)

[0381] [ka]

[0382] 5-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid (compound 125) was prepared from compound 124 using the procedure of example 9. LCMS (ESI) = 379.1 [M + H]+ .

[0383] Example 26: Synthesis of ethyl 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetate (Compound 126)

[0384] [ka]

[0385] Ethyl 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetate (compound 126) was prepared using the procedure of example 6, steps 4 and 5, except that ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate was used in step 4. LCMS (ESI)=410.2 [M+H] + .

[0386] Example 27: Synthesis of 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetic acid (Compound 127)

[0387] [ka]

[0388] 2-(4-(3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-1H-pyrazol-1-yl)acetic acid was prepared from compound 126 using the procedure of Example 9. LCMS (ESI) = 382.2 [M + H] + .

[0389] Example 28: Synthesis of 4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-propoxy-[1,1'-biphenyl]-3-carboxylic acid (Compound 128)

[0390] [ka]

[0391] 4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-propoxy-[1,1'-biphenyl]-3-carboxylic acid was prepared using the procedure of Example 6, except that 1-iodopropane was used in step 2. LCMS (ESI) = 392.1 [M+H] + .

[0392] Example 29: Synthesis of 5-([1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 129)

[0393] [ka]

[0394] 5-([1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 6, except that 4-bromobenzaldehyde was used in step 3. LCMS (ESI) = 290.1 ​​[M+H] + .

[0395] Example 30: Synthesis of 5-(4-cyclopropyl-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 130)

[0396] [ka]

[0397] Step 1: 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 106-A) (50.0 mg, 0.110 mmol, 1.00 equiv.) in toluene / water (1 / 0.10 mL), K 3 PO 4 To a stirred solution of cyclopropylboronic acid (69.8 mg, 0.329 mmol, 3.00 equiv), and cyclopropylboronic acid (18.8 mg, 0.219 mmol, 2.00 equiv), tricyclohexylphosphonium tetrafluoroborate (8.07 mg, 0.022 mmol, 0.20 equiv) and Pd(OAc) 2 (2.46 mg, 0.011 mmol, 0.10 equiv.) 2 The mixture was added at room temperature under atmospheric pressure. The resulting mixture was stirred at 100° C. overnight. The mixture was cooled to room temperature. The residue was purified by silica gel column chromatography to give 5-(4-cyclopropyl-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (36 mg, 79%) as an off-white solid. LCMS (ESI)=418.2[M+H] + .

[0398] Step 2: 5-(4-cyclopropyl-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (36.00 mg, 0.086 mmol, 1.00 equiv.) and 2,2,2-trifluoroacetaldehyde (1.00 mL) were added to an 8 mL vessel at room temperature. The resulting mixture was stirred at 80° C. for 1.5 hours. The resulting mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 5-(4-cyclopropyl-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 130) (9.5 mg, 32%) as a white solid. LCMS (ESI)=298.1 [M+H] + . 1 H NMR (300 MHz, DMSO-d 6 ):δ 11.12(s,1H),8.22(s,1H),7.84(d,J=8.1Hz,1H),6.88(d,J=1.2Hz,1H),6.78(dd,J=8.1,1.4Hz,1H), 4.20(q,J=7.0Hz,2H),2.06-1.92(m,1H),1.39(t,J=6.9Hz,3H),1.09-0.93(m,2H),0.86-0.71(m,2H).

[0399] Example 31: Synthesis of 5-(2-ethoxy-4-(1H-pyrazol-3-yl)phenyl)-1,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 131)

[0400] [ka]

[0401] 5-(2-ethoxy-4-(1H-pyrazol-3-yl)phenyl)-1,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 6, steps 4 and 5, except that 1H-pyrazol-3-yl)boronic acid was used in step 4. LCMS (ESI) = 324.1 [M + H]+ .

[0402] Example 32: Synthesis of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoic acid (compound 132)

[0403] [ka]

[0404] Step 1: 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (compound 101-A) (50 mg, 0.149 mmol, 1 equiv.), Pd(dppf)Cl in MeOH at room temperature 2 (10.9 mg, 0.015 mmol, 0.1 equiv.), and triethylamine (45.2 mg, 0.446 mmol, 3 equiv.) were added to a 30 mL pressure tank reactor. The mixture was stirred at 120° C. under 10 atm CO atmosphere for 3 h. The resulting mixture was concentrated under reduced pressure. The crude product (40 mg) was used directly in the next step without further purification. To obtain an analytical sample, the crude product (20 mg) was purified by preparative HPLC to give methyl 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoate (compound 132-A) (14.1 mg, 26%) as a white solid. LCMS (ESI)=316.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.47(s,1H),7.81(d,J=8.0Hz,1H),7.76-7.55(m,2H),4.21(q,J=6.9Hz,2H),3.91(s,3H),1.34(t,J=6.9Hz,3H).

[0405] Step 2: MeOH / H 2Methyl 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoate (30 mg, 0.09 mmol, 1 equiv.) and NaOH (11.4 mg, 0.28 mmol, 3 equiv.) in 2H2O (1 mL / 0.2 mL) were added to an 8 mL vial and the solution was stirred at room temperature for 2 h. The resulting mixture was filtered and the filter cake was washed with EtOAc (3x5 mL). The filtrate was concentrated under reduced pressure. The residue was dissolved in DMSO (3 mL) and purified by preparative separation to give 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoic acid (compound 132) (8.5 mg) as an off-white solid. LCMS(ESI)=302.1[M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.00(s,1H),7.83(d,J=7.8Hz,1H),7.64(d,J=10.4Hz,2H),4.21(q,J=6.9Hz,2H),1.36(t,J=6.9Hz,3H).

[0406] Example 33: Synthesis of 5-(2-ethoxy-4-(pyrrolidine-1-carbonyl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 133)

[0407] [ka]

[0408] To a stirred solution of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoic acid (50 mg, 0.166 mmol, 1 eq.) and DIEA (64.4 mg, 0.498 mmol, 3.0 eq.) in DMF (1 mL) was added HATU (75.7 mg, 0.199 mmol, 1.2 eq.) at room temperature. To the above mixture was added pyrrolidine (23.6 mg, 0.332 mmol, 2 eq.) at room temperature. The resulting mixture was stirred at room temperature overnight. The crude product was purified by preparative HPLC to give 5-(2-ethoxy-4-(pyrrolidine-1-carbonyl)phenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (5.1 mg, 8%) as a white solid. LCMS (ESI) = 355.4 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.32(s,1H),7.75(d,J=7.8Hz,1H),7.26(s,1H),7.20(d,J=7.9Hz,1H),4.24-4.12(m,2 H),3.49(t,J=6.0Hz,2H),3.41(t,J=5.8Hz,2H),1.95-1.79(m,4H),1.34(t,J=6.9Hz,3H).

[0409] Example 34: Synthesis of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-N-phenylbenzamide (Compound 134)

[0410] [ka]

[0411] 3-Ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-N-phenylbenzamide (compound 134) was prepared using the procedure of Example 33, except that aniline was used in the amide coupling step. LCMS (ESI) = 377.1 [M + H]+ . 1 H NMR (300MHz, DMSO-d 6 )δ12.30(s,1H),10.37(s,1H),7.86(d,J=7.5Hz,1H),7.79(d,J=7.7Hz,2H),7.73-7.65(m,2H ),7.39(t,J=7.9Hz,2H),7.14(t,J=7.4Hz,1H),4.27(q,J=6.9Hz,2H),1.38(t,J=6.8Hz,3H).

[0412] Example 35: Synthesis of 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (Compound 135)

[0413] [ka]

[0414] 3-Ethoxy-4-(7-oxo-6,7-dihydro-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (compound 135) was prepared using the procedure of Example 33, except that ammonium carbonate was used in the amide coupling step. LCMS (ESI) = 301.1 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.33(s,1H),8.15(s,1H),7.76(d,J=7.8Hz,1H),7.66-7.50(m,3H),4.21(q,J=7.1Hz,2H),1.36(t,J=6.9Hz,3H).

[0415] Example 36: Synthesis of N-cyclopentyl-3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (Compound 136)

[0416] [ka]

[0417] To an 8 mL vial was added methyl 3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzoate (50.0 mg, 0.159 mmol, 1.00 equiv.) and cyclopentanamine (67.5 mg, 0.793 mmol, 5.00 equiv.) at room temperature. The resulting mixture was stirred at 100° C. overnight. The mixture was cooled to room temperature. The resulting mixture was diluted with DMSO (3 mL). The mixture was purified by preparative HPLC to give N-cyclopentyl-3-ethoxy-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)benzamide (9.7 mg, 17%) as a white solid. LCMS(ESI)=369.2[M+H] + . 1 H NMR (300 MHz, DMSO-d 6 ):δ 12.26(s,1H),8.43(d,J=7.1Hz,1H),7.79(d,J=8.4Hz,1H),7.64-7.52(m,2H), 4.34-4.14(m,3H),2.03-1.84(m,2H),1.82-1.47(m,6H),1.37(t,J=6.9Hz,3H).

[0418] The following compounds (compounds 137-192) were prepared using similar methods as described in Examples 1-36.

[0419] [Table 1-1]

[0420] [Table 1-2]

[0421] [Table 1-3]

[0422] [Table 1-4]

[0423] [Table 1-5]

[0424] [Table 1-6]

[0425] [Table 1-7]

[0426] Example 37: Synthesis of (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate (Compound 193)

[0427] [ka]

[0428] 3'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (50.0 mg, 0.132 mmol, 1.0 equiv.), HATU (61.0 mg, 0.160 mmol, 1.2 equiv.), and DIEA (52.0 mg, 0.402 mmol, 3.0 equiv.) in DMF (1.00 mL) were added to an 8 mL vial. 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one (35.0 mg, 0.269 mmol, 2.0 equiv.) was added at room temperature, and the mixture was stirred for 6 h. The crude reaction (4 mL) was purified by preparative HPLC to give (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl) 3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylate (25.1 mg, 37%) as an off-white solid. LCMS (ESI) = 490.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ11.81(s,1H),8.18-8.04(m,2H),8.02-7.89(m,3H),7.48(d,J=7.2Hz,2 H),5.27(s,2H),4.32(q,J=6.9Hz,2H),2.25(s,3H),1.41(t,J=6.9Hz,3H).

[0429] Example 38: Synthesis of 3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 194)

[0430] [ka]

[0431] 3'-(Cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures of Examples 6 and 9, except that bromocyclopentane was used in Example 6, step 2. LCMS (ESI) = 418.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.08(dd,J=12.9,8.1Hz,3H),7.89(d,J=8.1Hz,2H),7.46(d,J=8.1Hz,2H),5.28-5.19(m,1H),2.09-1.82(m,4H),1.82-1.53(m,4H).

[0432] Example 39: Synthesis of 2'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 195)

[0433] [ka]

[0434] 2'-Ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures of Examples 6 and 9. LCMS (ESI) = 378.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.98(d,J=8.0Hz,2H),7.84(d,J=7.8Hz,2H),7.66(d,J=8.0Hz,2H),7.46(d,J=8.1Hz,1H),4.23(q,J=6.9Hz,2H),1.34(t,J=6.9Hz,3H).

[0435] Example 40: Synthesis of 2',6'-dimethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 196)

[0436] [ka]

[0437] 2',6'-Dimethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures of Examples 6 and 9. LCMS (ESI) = 394.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.96(d,J=8.2Hz,2H),7.57(s,2H),7.40(d,J=8.3Hz,2H),3.81(s,6H).

[0438] Example 41: Synthesis of 5-(3'-amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 197)

[0439] [ka]

[0440] 5-(3'-amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 6. LCMS (ESI) = 349.2 [M+H] + . 1 H NMR (300 MHz, DMSO-d 6):δ 11.97(s,1H),7.88(d,J=8.5Hz,1H),7.30(d,J=6.6Hz,2H),7.14(t,J=7.8Hz,1H),6.94(t,J=1. 9Hz,1H),6.89(d,J=7.6Hz,1H),6.71-6.58(m,1H),4.28(q,J=6.9Hz,2H),1.41(t,J=6.9Hz,3H).

[0441] Example 42: Synthesis of 3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 198)

[0442] [ka]

[0443] Process 1:N 2 A mixture of 5-(4-bromo-2-ethoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (1.00 g, 2.19 mmol, 1.0 equiv.) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane (1.11 g, 4.37 mmol, 2.0 equiv.) and KOAc (645 mg, 6.57 mmol, 3.0 equiv.) and Pd(dppf)Cl in 1,4-dioxane (10 mL) at room temperature under 2(160 mg, 0.219 mmol, 0.10 equiv) was added to a 40 mL vial. The resulting mixture was stirred at 100° C. for 2 h, after which the reaction was quenched by the addition of water (100 mL) at room temperature. The precipitated solid was collected by filtration, washed with water (2×10 mL) and petroleum ether (2×10 mL) and dried to give 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (1.3 g, crude) as a brown solid. LCMS (ESI)=502.2 [M+H] + .

[0444] Step 2: 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (50.0 mg, 0.099 mmol, 1.0 equiv.), 3-bromo-5-hydroxybenzoic acid (32.0 mg, 0.147 mmol, 1.5 equiv.), K 2 CO 3 (41.0mg, 0.297mmol, 3.0eq), Pd(dppf)Cl 2 (10 mg, 0.014 mmol, 0.14 equiv.), dioxane (1.0 mL), and H 2 O (0.10 mL) was added to an 8 mL vial. The resulting mixture was 2 The mixture was heated at 80° C. under reduced pressure for 2 hours and then cooled to room temperature. The mixture was acidified to pH 4 with HCl (aq.) and the precipitated solid was collected by filtration to give 3′-ethoxy-5-hydroxy-4′-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1′-biphenyl]-3-carboxylic acid (53 mg) as a brown solid. LCMS (ESI)=514.2[M+H] + .

[0445] Step 3: 3'-Ethoxy-5-hydroxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (53.0 mg, 0.103 mmol, 1.0 equiv.), trifluoroacetic acid (2.0 mL) were added to a vial. The resulting mixture was stirred at 80° C. for 2 hours. The mixture was cooled to room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by preparative HPLC to give 3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (6.3 mg, 16%) as an off-white solid. LCMS (ESI) = 394.1 [M+H] + .LCMS(ESI)=394.1[M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.00(s,1H),10.00(s,1H),7.90(d,J=8.2Hz,1H),7.71(s,1H),7.44-7.33(m,4H),4.31(q,J=6.8Hz,2H).

[0446] Example 43: Synthesis of 3'-(cyclopentyloxy)-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 199)

[0447] [ka]

[0448] 3'-(Cyclopentyloxy)-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared using the procedures of Examples 6 and 42, except that bromocyclopentane was used in Example 6, step 2. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ10.01(s,1H),7.96(d,J=8.2Hz,1H),7.70(s,1H),7.38(t,J=7.5Hz,4H),2.04-1.78(m,4H),1.67-1.61(m,4H).

[0449] Example 44: Synthesis of 3'-(cyclopentyloxy)-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 200)

[0450] [ka]

[0451] 3'-(Cyclopentyloxy)-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared using the procedure of Example 42. LCMS (ESI) = 434.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.02(s,1H),8.12(d,J=2.5Hz,1H),8.00-7.86(m,2H),7.46-7.33(m,2H ),7.08(d,J=8.5Hz,1H),5.22(s,1H),2.16-1.74(m,4H),1.76-1.47(m,4H).

[0452] Example 45: Synthesis of 3'-(cyclopentyloxy)-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 201)

[0453] [ka]

[0454] 3'-(Cyclopentyloxy)-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 42. LCMS (ESI) = 434.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.99(d,J=8.3Hz,1H),7.80(d,J=8.0Hz,1H),7.43-7.33(m,2H),7.12-7.01 (m,2H),5.18(s,1H),1.97-1.91(m,2H),1.87-1.81(m,2H),1.67-1.61(m,4H).

[0455] Example 46: Synthesis of 3'-(cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 202)

[0456] [ka]

[0457] 3'-(Cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 42. LCMS (ESI) = 434.2 [M+H]+ . 1 H NMR (300MHz, DMSO-d 6 )δ12.10(s,1H),7.91(dd,J=8.2,5.7Hz,2H),7.47(s,2H),7.38-7.26(m,2H),5.23(tt,J=5.7,2.7Hz,1H),2.04-1.77(m,4H),1.75-1.55(m,4H).

[0458] Example 47: Synthesis of 5-(3-ethoxy-3',5'-difluoro-4'-hydroxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 203)

[0459] [ka]

[0460] 5-(3-ethoxy-3',5'-difluoro-4'-hydroxy-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 42. LCMS (ESI) = 386.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ11.95(s,1H),7.91-7.82(m,1H),7.59(dd,J=8.3,1.7Hz,2H),7.42(d,J=6.8Hz,2H),4.32(q,J=6.9Hz,2H),1.40(t,J=6.9Hz,3H).

[0461] Example 48: Synthesis of 3-amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 204)

[0462] [ka]

[0463] 3-Amino-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was synthesized by the reaction of Pd(DTBPF)Cl 2 Prepared using the procedure of example 42, except that was used in step 2. LCMS (ESI) = 392.4 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.92(d,J=8.5Hz,1H),7.81(d,J=8.3Hz,1H),7.35(d,J=6.8Hz,2H),7.14(d,J=1. 8Hz,1H),6.92(dd,J=8.4,1.8Hz,1H),4.29(q,J=6.9Hz,2H),1.41(t,J=6.9Hz,3H).

[0464] Example 49: Synthesis of 3'-ethoxy-3-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 205)

[0465] [ka]

[0466] 3'-Ethoxy-3-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 48. LCMS (ESI) = 396.1 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.99(d,J=8.5Hz,1H),7.88(t,J=8.1Hz,1H),7.75-7.63(m,2H),7.52-7.44(m,2H),4.34(q,J=6.9Hz,2H),1.42(t,J=6.9Hz,3H).

[0467] Example 50: Synthesis of 3'-ethoxy-3-methoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 206)

[0468] [ka]

[0469] 3'-Ethoxy-3-methoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 48. LCMS (ESI) = 408.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.00(d,J=8.0Hz,2H),7.75(d,J=7.8Hz,2H),7.48(dd,J=9.6,1.5Hz,4H),7.42(s, 3H),7.38(d,J=1.5Hz,1H),4.34(q,J=6.9Hz,4H),3.96(s,6H),1.43(t,J=6.9Hz,6H).

[0470] Example 51: Synthesis of 3'-ethoxy-3-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 207)

[0471] [ka]

[0472] 3'-Ethoxy-3-methyl-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 48. LCMS (ESI) = 392.2 [M+H]+ . 1 H NMR (300MHz, DMSO-d 6 )δ12.89(s,1H),7.95(d,J=8.3Hz,1H),7.87(d,J=7.8Hz,1H),7.78-7.67(m,2H), 7.47(d,J=8.2Hz,2H),4.31(t,J=7.0Hz,2H),2.64(s,3H),1.40(t,J=7.0Hz,3H).

[0473] Example 52: Synthesis of 3'-ethoxy-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 208)

[0474] [ka]

[0475] 3'-Ethoxy-3-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared from methyl 4-bromo-2-hydroxybenzoate using the procedures of Examples 48 and 9. LCMS (ESI) = 394.01 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.87(d,J=8.4Hz,1H),7.74(d,J=7.8Hz,1H),7.37(d,J=6.5Hz,2H),6.99(d,J=10.9Hz,2H),4.31(q,J=6.9Hz,2H),1.39(t,J=6.9Hz,3H).

[0476] Example 53: Synthesis of 3'-(cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 209)

[0477] [ka]

[0478] 3'-(Cyclopentyloxy)-2-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared from methyl 3-bromo-2-hydroxybenzoate using the procedures of Examples 42 and 9. LCMS (ESI) = 434.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.06(s,1H),7.90(t,J=9.2Hz,2H),7.65(d,J=7.6Hz,1H),7.45(s,1H),7.38-7. 23(m,1H),7.01(t,J=7.8Hz,1H),5.06(s,1H),2.09-1.80(m,4H),1.60-1.80(m,4H).

[0479] Example 54: Synthesis of 3'-(cyclopentyloxy)-6-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 210)

[0480] [ka]

[0481] 3'-(Cyclopentyloxy)-6-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was prepared from methyl 3-bromo-4-hydroxybenzoate using the procedures of Examples 42 and 9. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ10.63(s,1H),7.99(d,J=8.2Hz,1H),7.93(d,J=2.2Hz,1H),7.83(dd,J=8.5,2.2Hz,1H),7.39(d,J=1.6Hz,1H) ,7.28(dd,J=8.1,1.5Hz,1H),7.06(d,J=8.4Hz,1H),5.06(d,J=3.5Hz,1H),1.80-2.00(m,4H),1.80-1.51(m,4H).

[0482] Example 55: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetic acid (Compound 211)

[0483] [ka]

[0484] Step 1: To a 40 mL vial was added 4-bromophenol (1.00 g, 5.78 mmol, 1.0 equiv), DMF (10 mL). To the above mixture was added potassium carbonate (420 mg, 17.5 mmol, 3.0 equiv) in portions at 0° C. The resulting mixture was stirred at 0° C. for an additional 30 min. To the above mixture was added tert-butyl 2-bromoacetate (1.40 g, 7.18 mmol, 1.24 equiv). The resulting mixture was stirred at room temperature until TLC analysis showed consumption of starting material. The resulting mixture was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (3×100 mL) and washed with anhydrous Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure to give tert-butyl 2-(4-bromophenoxy)acetate (1.1 g, 66%) as a colorless oil.

[0485] Step 2: tert-Butyl 2-(4-bromophenoxy)acetate (300 mg, 1.04 mmol, 1.0 equiv), bis(pinacolato)diboron (293 mg, 1.15 mmol, 1.1 equiv), Pd(dppf)Cl 2 (60.0 mg, 0.082 mmol, 0.08 equiv), KOAc (308 mg, 3.14 mmol, 3.0 equiv), and dioxane (5.0 mL) were added to a 40 mL vial. The resulting mixture was cooled to 5° C. for 24 hours and then cooled to 5° C. 2 The mixture was stirred at 80° C. for 4 hours under reduced pressure. The residue was purified by silica gel column chromatography to give tert-butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (240 mg, 69%) as a colorless oil. LCMS (ESI)=333.2 [MH] + .

[0486] Step 3: tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (80 mg, 0.239 mmol, 1.0 equiv.), 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (120 mg, 0.36 mmol, 1.5 equiv.), K 2 CO 3 (99.0mg, 0.716mmol, 3.0eq), Pd(dppf)Cl 2 (16.0 mg, 0.022 mmol, 0.09 equiv.), dioxane (2.0 mL), and H 2 O (0.20 mL) was added to an 8 mL vial. The resulting mixture was 2 The mixture was stirred at 100° C. for 16 h under reduced pressure. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give tert-butyl 2-((3′-ethoxy-4′-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1′-biphenyl]-4-yl)oxy)acetate (75 mg, 68%) as an off-white solid.

[0487] Step 4: tert-Butyl 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetate (75.0 mg, 0.162 mmol, 1.0 equiv) and 1M HCl / EtOAc (10 mL) were added to a 50 mL round-bottom flask. The resulting mixture was stirred at 50° C. for 16 h. The crude product was purified by preparative HPLC to give 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)oxy)acetic acid (19.6 mg, 30%) as an off-white solid. LCMS (ESI) = 408.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.06(s,1H),7.88(d,J=8.3Hz,1H),7.74(d,J=8.7Hz,2H),7.38(m,2H),7. 05(d,J=8.7Hz,2H),4.75(s,2H),4.31(q,J=6.9Hz,2H),1.40(t,J=6.9Hz,3H).

[0488] Example 56: Synthesis of (±)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 212)

[0489] [ka]

[0490] A stirred solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.00 g, 4.54 mmol, 1.0 equiv.) and methyl 2-bromopropanoate (1.14 g, 6.82 mmol, 1.5 equiv.) in DMF (10.0 mL) was added to the flask at room temperature. 2 CO 3(1.26 g, 9.09 mmol, 2.0 equiv.) was added. The resulting mixture was stirred at 60° C. for 16 h, after which the mixture was diluted with water (30 mL) and extracted with EtOAc (2×20 mL). The combined organic layers were washed with brine (20 mL) and extracted with anhydrous Na 2 SO 4 The mixture was dried over 100 ml, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl 2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanoate (520 mg, 37%) as a white solid. 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedures of Examples 1 and 9. LCMS (ESI) = 422.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.00(d,J=8.5Hz,1H),7.39-7.25(m,3H),7.25-7.12(m,2H),6.82(d,J=8.0Hz,1H),4.45-4.25(m,3H),1.47-1.36(m,6H).

[0491] Example 57: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-methylpropanoic acid (Compound 213)

[0492] [ka]

[0493] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-methylpropanoic acid was prepared using the procedures of Examples 56, 1, and 9. LCMS (ESI) = 436.2 [M+H] + . 1 H NMR (300 MHz, DMSO-d 6 ):δ 7.96(d,J=8.5Hz,1H),7.41-7.28(m,4H),7.20(s,1H),6.89(d,J=7.1Hz,1H),4.31(q,J=6.9Hz,2H),1.55(s,5H),1.42(t,J=6.9Hz,3H).

[0494] Example 58: Synthesis of (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 214)

[0495] [ka]

[0496] Step 1: tert-Butyl N-(3-bromophenyl)carbamate (1.00 g, 3.68 mmol, 1.0 equiv), tert-butyl 2-bromoacetate (1.07 g, 5.51 mmol, 1.5 equiv), NaH (220 mg, 5.51 mmol, 1.5 equiv, 60%), and DMF (10.0 mL) were added to a 40 mL vial at room temperature. The mixture was stirred for 1 h, after which the reaction was quenched with ice water (50 mL). The resulting mixture was extracted with EtOAc (2×20 mL). The combined organic layers were washed with brine (1×20 mL) and washed with anhydrous Na 2 SO 4The mixture was dried over 100 ml, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give tert-butyl N-(3-bromophenyl)-N-(tert-butoxycarbonyl)glycinate (800 mg, 56%) as a colorless oil. LCMS (ESI) = 372 [M + H] + .

[0497] Step 2: tert-Butyl N-(3-bromophenyl)-N-(tert-butoxycarbonyl)glycinate (300 mg, 0.777 mmol, 1.0 equiv.), bis(pinacolato)diboron (296 mg, 1.16 mmol, 1.5 equiv.), Pd(dppf)Cl 2 (56.8 mg, 0.078 mmol, 0.10 equiv), KOAc (229 mg, 2.33 mmol, 3.0 equiv), and dioxane (5 mL) were added to an 8 mL vial. The mixture was stirred at 100° C. for 2 h. The resulting mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give tert-butyl N-(tert-butoxycarbonyl)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)glycinate (270 mg, 80%) as a colorless oil.

[0498] Step 3: 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (70.0 mg, 0.208 mmol, 1.0 equiv.), tert-butyl N-(tert-butoxycarbonyl)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)glycinate (135 mg, 0.312 mmol, 1.5 equiv.), K 2 CO 3 (57.6mg, 0.416mmol, 2.0eq), Pd(dppf)Cl 2 (15.2 mg, 0.021 mmol, 0.1 equiv.), dioxane (1 mL), and H 20 (0.3 mL) was added to an 8 mL vial. The resulting mixture was stirred at 100° C. for 16 h. The mixture was cooled to room temperature and acidified to pH 6-7 with 2 M HCl. The mixture was purified by silica gel column chromatography to give tert-butyl N-(tert-butoxycarbonyl)-N-(3′-ethoxy-4′-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)glycinate (50 mg, 43%) as an off-white solid.

[0499] Step 4: tert-Butyl N-(tert-butoxycarbonyl)-N-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycinate (50.0 mg, 0.089 mmol, 1.0 equiv.) and TFA (1.0 mL) were added to an 8 mL vial at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The resulting mixture was diluted with DMSO (2 mL) and then purified by preparative HPLC to give (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (9.1 mg, 25%) as a white solid. LCMS (ESI) = 407.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.95(d,J=8.4Hz,1H),7.32(dd,J=4.4,2.8Hz,2H),7.21(t,J=7.8Hz,1H),6.95(d,J=9. 1Hz,2H),6.62(d,J=8.5Hz,1H),4.30(q,J=6.8Hz,2H),3.86(s,2H),1.42(t,J=6.9Hz,3H).

[0500] Example 59: Synthesis of (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)glycine (Compound 215)

[0501] [ka]

[0502] (3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-yl)glycine was prepared using the procedure of Example 58. LCMS (ESI) = 407.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.95(d,J=8.6Hz,1H),7.56(d,J=8.6Hz,2H),7.36-7.27(m,2H),6.68(d ,J=8.6Hz,2H),4.31(q,J=6.9Hz,2H),3.82(s,2H),1.43(t,J=6.9Hz,3H).

[0503] Example 60: Synthesis of 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 216)

[0504] [ka]

[0505] Step 1: 5-(4-bromo-2-(cyclopentyloxy)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (200 mg, 0.403 mmol, 1.0 equiv.) and tert-butyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate (202 mg, 0.604 mmol, 1.5 equiv.), K 2 CO 3 (167mg, 1.21mmol, 3.0eq), Pd(dppf)Cl 2 CH 2 Cl 2 (32.9 mg, 0.040 mmol, 0.10 equiv.), dioxane (3.0 mL), and H 2 O (0.30 mL) was added to an 8 mL vial. The mixture was stirred at 100° C. for 2 h. The mixture was cooled to room temperature and the residue was purified by silica gel column chromatography to give tert-butyl 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (250 mg) as an off-white solid.

[0506] Step 2: tert-Butyl 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetate (250 mg, 0.401 mmol, 1.0 equiv) in EA (5.0 mL of saturated solution) and HCl (gas) were added to a 40 mL vial. The resulting mixture was stirred at 50° C. for 3 h. The resulting mixture was concentrated under reduced pressure to give 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (200 mg), which was used in the next step without further purification.

[0507] Step 3: 2-((3'-(cyclopentyloxy)-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (200 mg, 0.352 mmol, 1.0 equiv) and TFA (3.0 mL) were added to an 8 mL vial. The mixture was stirred at 60° C. for 2 h. The mixture was concentrated under reduced pressure and the crude residue was purified by preparative HPLC to give 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (19.6 mg, 12%) as a white solid. LCMS (ESI) = 448.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.05(d,J=8.4Hz,1H),7.46-7.36(m,3H),7.33(d,J=7.8Hz,1H),7.24(s,1H),6.9 6(d,J=8.2Hz,1H),5.23(s,1H),4.68(s,2H),2.02-1.86(m,4H),1.81-1.51(m,4H).

[0508] Example 61: Synthesis of 2-((2'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid (Compound 217)

[0509] [ka]

[0510] 2-((2'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid was prepared using the procedure of Example 60. LCMS (ESI) = 408.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.68(s,1H),7.88-7.79(m,2H),7.50(d,J=8.3Hz,1H),7.36(t,J=7.9Hz,1H),7.23-7.09( m,2H),6.92(dd,J=8.7,2.6Hz,1H),4.72(s,2H),4.22(q,J=6.9Hz,2H),1.35(t,J=6.9Hz,3H).

[0511] Example 62: Synthesis of methyl 3'-ethoxy-5-(2-methoxy-2-oxoethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate (Compound 218)

[0512] [ka]

[0513] Methyl 3'-ethoxy-5-(2-methoxy-2-oxoethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylate was prepared from methyl 3-bromo-5-hydroxybenzoate and methyl bromoacetate using the procedure of Example 55. LCMS (ESI) = 480.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.99(d,J=8.5Hz,1H),7.90(s,1H),7.63(s,1H),7.51-7.41(m,3H),5.03(s ,2H),4.35(t,J=6.9Hz,2H),3.91(s,3H),3.73(s,3H),1.42(t,J=6.9Hz,3H).

[0514] Example 63: Synthesis of 5-(carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid (Compound 219)

[0515] [ka]

[0516] 5-(Carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-carboxylic acid was synthesized from compound 218 using the procedure of Example 9. LCMS (ESI) = 452.1 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.01(d,J=8.1Hz,1H),7.78(s,1H),7.32(m,4H),4.47-4.24(m,4H),1.42(t,J=7.0Hz,3H).

[0517] Example 64: Synthesis of 3-(carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (compound 220)

[0518] [ka]

[0519] 3-(Carboxymethoxy)-3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was synthesized from methyl 4-bromo-2-hydroxybenzoate and methyl bromoacetate using the procedures of Examples 55, 42, and 9. LCMS (ESI) = 452.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.25(s,1H),7.86(d,J=8.4Hz,1H),7.67(d,J=8.0Hz,1H),7.57(s,1H),7. 46(d,J=6.7Hz,3H),4.79(s,2H),4.32(q,J=6.9Hz,2H),1.39(t,J=6.9Hz,3H).

[0520] Example 65: Synthesis of tert-butyl (3'-ethoxy-4-((4-methoxybenzyl)oxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycinate (Compound 221)

[0521] [ka]

[0522] Step 1: 4-Bromo-2-nitrophenol (1.00 g, 4.59 mmol, 1.0 equiv), 4-chloroanisole (0.90 g, 6.31 mmol, 1.4 equiv), K2 CO 3 (1.90 g, 13.7 mmol, 3.0 equiv.) and acetone (20 mL) were placed in a 100 mL round bottom flask. The resulting solution was stirred at 60° C. overnight. The resulting mixture was concentrated under vacuum and the residue was purified by silica gel chromatography using ethyl acetate / petroleum ether (5 / 95) to give 4-bromo-1-((4-methoxybenzyl)oxy)-2-nitrobenzene (850 mg, 57%) as a yellow oil. LCMS (ESI)=338.0 [M+H] + .

[0523] Step 2: EtOH (20 mL) and H 2 4-Bromo-1-((4-methoxybenzyl)oxy)-2-nitrobenzene (850 mg, 2.51 mmol, 1.0 equiv) in 2 mL of O, NH 4 Cl (668 mg, 12.5 mmol, 5.0 equiv), Fe (420 mg, 7.52 mmol, 3.0 equiv) were added to a 100 mL round bottom flask. The resulting solution was stirred at 70° C. for 20 min. The solid was filtered and the resulting mixture was concentrated in vacuo to give 5-bromo-2-((4-methoxybenzyl)oxy)aniline (700 mg, 90%) as a brown solid. LCMS (ESI)=308.0 [M+H] + .

[0524] tert-Butyl (3'-ethoxy-4-((4-methoxybenzyl)oxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycinate (compound 221) was prepared using the procedure of Example 58. LCMS (ESI) = 599.3 [M + H] + . 1 H NMR (300MHz, DMSO-d 6)δ12.14(s,1H),7.84(d,J=8.2Hz,1H),7.49-7.40(m,2H),7.34(d,J=7.5Hz,2H),7.09-6.95(m,3H),6.97(d,J=2.0Hz,1H),6.79(d,J=1.9 Hz,1H),5.26(t,J=5.9Hz,1H),5.13(s,2H),4.29(q,J=6.9Hz,2H),3.98(d,J=5.9Hz,2H),3.78(s,3H),1.43(s,9H),1.39(t,J=6.9Hz,3H).

[0525] Example 66: Synthesis of (3'-ethoxy-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 222)

[0526] [ka]

[0527] (3'-ethoxy-4-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine was prepared from compound 221 using the method of Example 55, step 4. LCMS (ESI) = 423.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.01(d,J=8.2Hz,1H),7.29(d,J=7.7Hz,2H),6.84(s,1H),6.81-6.70(m,2H),4.30(t,J=6.9Hz,2H),3.71(s,2H),1.44(t,J=6.9Hz,3H).

[0528] Example 67: Synthesis of (3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 223)

[0529] [ka]

[0530] (3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine was prepared from 3-bromo-5-nitrophenol and 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one using the procedures of Examples 65 and 60. LCMS (ESI) = 423.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ9.20(s,1H),7.93(d,J=8.4Hz,1H),7.25(dt,J=4.6,2.3Hz,2H),6.43-6.32(m,2H) ),6.04(d,J=2.1Hz,1H),4.28(q,J=6.8Hz,2H),3.78(s,2H),1.42(t,J=6.9Hz,3H).

[0531] Example 68: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)-2-methylpropanoic acid (Compound 224)

[0532] [ka]

[0533] In a 40 mL vial, add 3-bromoaniline (1.00 g, 5.81 mmol, 1.0 equiv.), tert-butyl 2-bromo-2-methylpropanoate (1.50 g, 6.72 mmol), NaHCO in DMF (10 mL). 3(1.50 g, 17.9 mmol) was heated for 16 h at 140° C. The mixture was cooled to room temperature and the residue was purified by silica gel column chromatography to give tert-butyl 2-((3-bromophenyl)amino)-2-methylpropanoate (120 mg, 7%) as a brown oil. 1 H NMR (300 MHz, CDCl 3 )δ7.03(t,J=8.0Hz,1H),6.95-6.82(m,2H),6.63(d,J=8.0Hz,1H),1.55(s,6H),1.43(s,9H).

[0534] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)-2-methylpropanoic acid was prepared from 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one using similar methods as described in Examples 42 and 60. 1 H NMR (300MHz, DMSO-d 6 )δ11.94(s,1H),7.87(d,J=8.3Hz,1H),7.30-7.13(m,3H),6.93(d,J=7.6Hz,1H),6.86(t,J =2.0Hz,1H),6.59-6.50(m,1H),4.27(q,J=6.8Hz,2H),1.48(s,6H),1.41(t,J=6.9Hz,3H).

[0535] Example 69: Synthesis of (3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine (Compound 225)

[0536] [ka]

[0537] (3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)glycine was prepared using the procedure of Example 58. LCMS (ESI) = 447.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.03(s,1H),7.92(d,J=8.4Hz,1H),7.34(dq,J=3.5,1.6Hz,2H),7.23(t,J=7.8Hz,1H),7.02-6.92(m,2H) ,6.67(dd,J=7.8,2.2Hz,1H),5.15(dt,J=5.7,3.0Hz,1H),3.92(s,2H),2.06-1.79(m,4H),1.77-1.53(m,4H).

[0538] Example 70: Synthesis of 3-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)propanoic acid (Compound 226)

[0539] [ka]

[0540] 5-(3′-amino-3-ethoxy-[1,1′-biphenyl]-4-yl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 1.

[0541] Step 1: To a stirred solution of 5-(3'-amino-3-ethoxy-[1,1'-biphenyl]-4-yl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (80.0 mg, 0.171 mmol, 1.0 equiv) and ethyl 3-oxopropanoate (0.50 mL) in AcOH (1.0 mL) was added NaBH(OAc) 3 (362 mg, 1.71 mmol, 10 equiv) was added in portions at room temperature. The resulting mixture was stirred for 10 min, and then the resulting mixture was diluted with water (10 mL). The mixture was diluted with NaHCO 3 The mixture was basified to pH 8 with EA (3×10 mL) and the resulting mixture was extracted with EA (3×10 mL). The combined organic layers were washed with brine (20 mL) and diluted with anhydrous Na 2 SO 4 The mixture was dried over 1000 ml, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 3-((3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)propanoate (65 mg, 40%) as a pale yellow solid.

[0542] 3-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)amino)propanoic acid was prepared using the procedures of Examples 6 and 9. LCMS (ESI) = 421.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.91(d,J=8.3Hz,1H),7.33(d,J=7.4Hz,2H),7.21(t,J=7.9Hz,1H),6.97-6.88(m,2H),6.64(dd,J=7 .3,1.9Hz,1H),4.29(q,J=6.9Hz,2H),3.33(t,J=6.7Hz,2H),2.58-2.50(m,2H),1.40(t,J=6.9Hz,3H).

[0543] Example 71: Synthesis of 4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy-[1,1'-biphenyl]-4-carboxylic acid (Compound 227)

[0544] [ka]

[0545] 5-(4-Bromo-2-methoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared using the procedure of Example 6.

[0546] Step 1: To a stirred solution of 5-(4-bromo-2-methoxyphenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (500 mg, 1.13 mmol, 1.0 equiv) in DMF (5.0 mL) was added NaH (90.4 mg, 2.26 mmol, 2.0 equiv, 60%) with N 2 The mixture was stirred at room temperature for 30 min, then 4-methoxybenzyl chloride (212 mg, 1.36 mmol, 1.2 equiv) was added dropwise. The resulting mixture was stirred for 24 h, then quenched by the addition of water (20 mL). The mixture was extracted with EA (2×20 mL) and the combined organic layers were washed with brine (20 mL) and washed with anhydrous Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5-(4-bromo-2-methoxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (370 mg, 58%) as a yellow solid.

[0547] Step 2: To a stirred solution of 5-(4-bromo-2-methoxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (250 mg, 0.445 mmol, 1.0 equiv) in DMF (5.0 mL) was added LiCl (188 mg, 4.44 mmol, 10 equiv). The resulting mixture was stirred at 150° C. for 9 h and then cooled to room temperature. The reaction was quenched by the addition of water (20 mL) and acidified to pH 3-4 with concentrated HCl. The mixture was extracted with EA (3×10 mL) and the combined organic layers were washed with brine (20 mL) and diluted with anhydrous Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5-(4-bromo-2-hydroxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (230 mg, 55%) as a grey solid.

[0548] Step 3: Dioxane (3.0 mL) and H 2 To a solution of 5-(4-bromo-2-hydroxyphenyl)-3,6-bis(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (200 mg, 0.212 mmol, 1.0 equiv) and 4-(ethoxycarbonyl)phenylboronic acid (61.6 mg, 0.317 mmol, 1.5 equiv) in 2HO (0.30 mL) was added 10 mL of KCl. 2 CO 3 (87.7 mg, 0.635 mmol, 3.0 equiv.) and Pd(dppf)Cl 2 CH 2 Cl 2 (15.5 mg, 0.021 mmol, 0.10 equiv.) was added. 2After stirring at 100° C. for 2 h under reduced pressure, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give ethyl 4'-(3,6-bis(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-hydroxy-[1,1'-biphenyl]-4-carboxylate (150 mg, 34%) as a grey solid.

[0549] Step 4: To a stirred solution of ethyl 4'-(3,6-bis(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-hydroxy-[1,1'-biphenyl]-4-carboxylate (150 mg, 0.243 mmol, 1.0 equiv.) and 1-(2-chloroethyl)pyrrolidine hydrochloride (12.4 mg, 0.073 mmol, 1.0 equiv.) in DMF (2.0 mL) was added K 2 CO 3 (30.2 mg, 0.219 mmol, 3.0 equiv) was added at room temperature. The resulting mixture was stirred at 80° C. for 2 h. The resulting mixture was diluted with water (10 mL). The resulting mixture was extracted with EA (3×5 mL). The combined organic layers were washed with brine (10 mL) and washed with anhydrous Na 2 SO 4 The mixture was dried at 40° C. for 1 hour. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 4'-(3,6-bis(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylate (65 mg, 37%) as a yellow solid.

[0550] 4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedures of Examples 6 and 9. LCMS (ESI) = 447.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.06(d,J=8.3Hz,2H),8.02-7.91(m,3H),7.64(d,J=1.7Hz,1H),7.53(d d,J=8.1,1.6Hz,1H),4.54(s,2H),3.01(s,2H),2.77(s,4H),1.76(s,4H).

[0551] Example 72: Synthesis of 3'-(2-(dimethylamino)ethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 228)

[0552] [ka]

[0553] 3'-(2-(dimethylamino)ethoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 71. LCMS (ESI) = 421.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.13-8.04(m,2H),8.00-7.91(m,2H),7.81(d,J=8.0Hz,1H),7.62-7.50(m,2H),4.62(d,J=5.1Hz,2H),3.53-3.45(m,2H),2.82(s,6H).

[0554] Example 73: Synthesis of 3'-(3-(dimethylamino)propoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid (Compound 229)

[0555] [ka]

[0556] 3'-(3-(dimethylamino)propoxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-4-carboxylic acid was prepared using the procedure of Example 71. LCMS (ESI) = 435.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ11.06(s,1H),8.33(s,1H),8.02-7.93(m,3H),7.79(d,J=8.1Hz,2H),7.42(d,J=8.9H z,2H),4.30(t,J=6.1Hz,2H),2.57(t,J=7.0Hz,2H),2.26(s,6H),1.99(q,J=6.6Hz,2H).

[0557] Example 74: Synthesis of (4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-3-yl)glycine (Compound 230)

[0558] [ka]

[0559] (4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-3'-(2-(pyrrolidin-1-yl)ethoxy)-[1,1'-biphenyl]-3-yl)glycine was prepared using the procedure of example 71, except that alkylation with 1-(2-chloroethyl)pyrrolidine hydrochloride was performed in step 2, and the remaining steps were carried out as in example 58. LCMS (ESI) = 476.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.93(d,J=8.1Hz,1H),7.46(d,J=1.6Hz,1H),7.38(dd,J=8.0,1.5Hz,1H),7.21(t,J=7.8Hz,1H),7.0 2-6.91(m,2H),6.64(d,J=8.3Hz,1H),4.51(s,2H),3.90(s,2H),3.03(s,2H),2.79(s,4H),1.77(s,4H).

[0560] Example 75: Synthesis of 6-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid (Compound 231)

[0561] [ka]

[0562] 6-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)nicotinic acid was prepared from 6-bromonicotinic acid using the procedure of Example 42. LCMS (ESI) = 419.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ13.6(broad s,1H),12.2(broad s,1H),9.20(s,1H),8.39(dd,J=8.1,2.1Hz,1H),8.26(d,J=8.4Hz,1H),7. 80-8.00(m,3H),5.10-5.20(m,1H),1.75-2.05(m,4H),1.55-1.75(m,4H).

[0563] Example 76: Synthesis of 5-(3-ethoxy-3'-(methylamino)-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (Compound 232)

[0564] [ka]

[0565] 5-(3-ethoxy-3'-(methylamino)-[1,1'-biphenyl]-4-yl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one was prepared from N-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline using the procedure of Example 6. LCMS (ESI) = 363.2 [M+H] + .

[0566] Example 77: Synthesis of 5-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid (Compound 233)

[0567] [ka]

[0568] 5-(3-(cyclopentyloxy)-4-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)picolinic acid was prepared from methyl 5-bromopicolinate using the procedures of Examples 42 and 9. LCMS (ESI) = 419.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ11.7(broad s,1H),9.11(s,1H),8.38(d,J=8.4Hz,1H),8.10-8.18(m,1H),8.14(s,1H),8.03(d,J= 7.8,1H),7.50-7.60(m,2H),5.18-5.28(m,1H),1.80-2.00(m,4H),1.55-1.75(m,4H).

[0569] Example 78: Synthesis of 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid (compound 234)

[0570] [ka]

[0571] 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)propanoic acid was prepared from 3-(3-bromophenyl)propanoic acid using the procedure of Example 42. LCMS (ESI) = 406.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.17(s,2H),7.87(d,J=8.1Hz,1H),7.69-7.56(m,2H),7.41(d,J=7.5Hz,3H),7.35-7.26( m,1H),4.31(q,J=6.9Hz,2H),2.93(t,J=7.7Hz,2H),2.68-2.52(m,2H),1.40(t,J=6.9Hz,3H).

[0572] Example 79: Synthesis of (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)acrylic acid (Compound 235)

[0573] [ka]

[0574] (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)acrylic acid was prepared from (E)-3-(3-bromophenyl)acrylic acid using the procedure of Example 42. LCMS (ESI) = 404.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.12(s,1H),7.92(d,J=8.1Hz,1H),7.88-7.66(m,3H),7.56(t,J=7.7Hz,1H),7.49( d,J=8.1Hz,2H),6.72(d,J=16.0Hz,1H),4.34(q,J=6.8Hz,2H),1.41(t,J=6.9Hz,3H).

[0575] Example 80: Synthesis of (Z)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid (Compound 236) and (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid (Compound 237)

[0576] [ka]

[0577] Step 1: In a 50 mL round-bottom flask, add dioxane (0.50 mL) and H 2 3-Bromobenzaldehyde (1.84 g, 9.94 mmol, 1.00 equiv.) and methyl acrylate (2.57 mg, 29.8 mmol, 3.00 equiv.) in 2H2O (0.50 mL) were added to DABCO (1.12 g, 9.94 mmol, 1.00 equiv.). The resulting solution was stirred at room temperature for 14 h. The residue was chromatographed on a silica gel column with ethyl acetate / petroleum ether (1:10). This gave 2.5 g (93%) of methyl 2-((3-bromophenyl)(hydroxy)methyl)acrylate as a colorless oil. 1 H NMR (300MHz, DMSO-d 6 )δ7.78-7.35(m,2H),6.24(t,J=1.5Hz,2H),6.20(s,1H),6.02(s,1H),5.88(brs,1H),5.43(d,J=1.5Hz,1H),3.62(s,3H).

[0578] Step 2: To methyl 2-((3-bromophenyl)(hydroxy)methyl)acrylate (250 mg, 0.922 mmol, 1.00 equiv.) was added THF (2.0 mL) and I2 (515 mg, 2.03 mmol, 2.20 equiv.). The resulting brown solution was cooled to 0 °C. NaBH 4 (69.8 mg, 1.84 mmol, 2.00 equiv) was added portionwise and the white suspension was stirred for 17 h. The reaction was cooled to 0 °C and cooled to H 2 The mixture was quenched by the addition of 2H2O (5 ml). The resulting mixture was extracted with DCM (3x5 ml). The combined organic layers were washed with NaCl (5 mL) and anhydrous Na 2 SO 4 The mixture was dried over 100 ml, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl (E)-3-(3-bromophenyl)-2-acrylate (40 mg, 17%) as a yellow oil. 1 H NMR (300 MHz, CDCl 3)δ7.63(s,1H),7.55(s,1H),7.48(dt,J=7.3,1.9Hz,1H),7.41-7.23(m,2H),3.85(s,3H),2.13(d,J=1.5Hz,3H).

[0579] Step 3: Dioxane (1.0 mL) and H 2 To a solution of 5-(2-ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(4-methoxybenzyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (94.7 mg, 0.188 mmol, 1.20 equiv.) and methyl (2E)-3-(3-bromophenyl)-2-methylprop-2-enoate (40.0 mg, 0.157 mmol, 1.00 equiv.) in 2H2O (0.1 mL) was added 2 CO 3 (65.0 mg, 0.470 mmol, 3.00 equiv.) and Pd(dppf)Cl 2 (11.5 mg, 0.016 mmol, 0.10 equiv.) was added. After stirring at 100° C. for 2 h under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl (E)-3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-acrylate (100 mg) as a white solid. LCMS (ESI)=552.2[M+H] + .

[0580] Step 4: Methyl (E)-3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-acrylate (40.0 mg, 0.073 mmol, 1.00 equiv) in trifluoroacetic acid (1.0 mL) was placed in an 8 mL vial. The resulting solution was stirred at 80° C. for 2 hours and then concentrated under reduced pressure. This gave 40 mg of methyl (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-acrylate as a yellow solid, which was carried on without further purification. LCMS (ESI) = 432.2 [M+H] + .

[0581] Step 5: Methyl (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-acrylate (40.0 mg) in DMSO (1.0 mL) was placed in an 8 mL vial, followed by the addition of 2N NaOH (1.0 mL). The resulting solution was stirred at room temperature for 2 hours. The pH was adjusted to pH 6 by the addition of AcOH. The crude product was purified by preparative HPLC to give 1.6 mg (4.0%) of (Z)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid (peak 1) as a white solid and 8.3 mg (21%) of (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid (peak 2) as a white solid.

[0582] (Z)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid data: LCMS (ESI) = 418.0 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ11.02(brs,1H) 8.01(d,J=8.4Hz,1H),7.81(s,1H),7.59(d,J=7.2Hz,1H),7.48-7.36(m,4H),4.35-4.28(m,2H),2.03(d,J=1.2Hz,3H),1.44(d,J=6.9Hz,3H).

[0583] (E)-3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylacrylic acid data: LCMS (ESI) = 418.0 [M + H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.00(d,J=8.1Hz,1H),7.84(s,1H),7.77(d,J=7.8Hz,1H),7.72(s,1H),7.60-7.51(m,2H) ,7.44(d,J=6.9Hz,2H),4.33(q,J=6.9Hz,2H),2.10(d,J=1.2Hz,3H),1.43(t,J=6.6Hz,3H).

[0584] Example 81: Synthesis of 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropanoic acid (Compound 238)

[0585] [ka]

[0586] To a solution of methyl (E)-3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methyl acrylate (60.0 mg, 0.109 mmol, 1.00 equiv.) in MeOH (1.0 mL) was added Pd / C (10.0 mg). Hydrogen was introduced by a hydrogen balloon and the mixture was stirred at room temperature for 2 h. The mixture was filtered through a celite pad and concentrated under reduced pressure. This gave methyl 3-(3'-ethoxy-4'-(3-(4-methoxybenzyl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropanoate (40 mg, 66%) as a white solid. LCMS (ESI) = 554.3 [M+H] + .

[0587] 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2-methylpropanoic acid was prepared using the procedures of Examples 6 and 9. LCMS (ESI) = 420.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.00(d,J=8.4Hz,1H),7.61(d,J=1.8Hz,2H),7.44-7.37(m,3H),7.24(d,J=7.5Hz,1H),4.33(q, J=6.9Hz,2H),3.05-2.96(m,1H),2.77-2.70(m,2H),1.43(t,J=6.9Hz,3H),1.10(d,J=6.3Hz,3H).

[0588] Example 82: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (Compound 239)

[0589] [ka]

[0590] Step 1: To a stirred solution of ethyl butyrate (1.00 g, 8.61 mmol, 1.00 equiv) in THF (20 mL) was added LDA (2 M) (4.74 mL) with N 2 The resulting mixture was cooled to -78 °C and cooled to -10 °C. 2 The mixture was stirred at -30° C. for 1.5 h under reduced pressure. To the above mixture, 1-bromo-3-(bromomethyl)benzene (2.37 g, 9.47 mmol, 1.1 equiv) was added dropwise over 15 min at -30° C. The resulting mixture was stirred at -30° C. for an additional 3 h. The reaction was quenched by the addition of 1 M HCl (20 mL) at 5° C. The resulting mixture was diluted with Et 2 The combined organic layers were washed with brine (2x20 mL) and extracted with anhydrous Na 2 SO 4 The mixture was dried over 100 ml, filtered and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give ethyl 2-(3-bromobenzyl)butanoate (800 mg, 26.4%) as a white solid.

[0591] Step 2: Ethyl 2-(3-bromobenzyl)butanoate (800 mg, 2.80 mmol, 1.00 equiv) and bis(pinacolato)diboron (1.42 g, 5.61 mmol, 2.0 equiv), KOAc (551 mg, 5.61 mmol, 2.0 equiv), dioxane (10.0 mL), Pd(dppf)Cl 2 (205 mg, 0.281 mmol, 0.1 equiv) was added to a 20 ml vial at room temperature. The resulting mixture was stirred at 100° C. for 2 h, and then the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)butanoate (700 mg, 62%) as a white solid.

[0592] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid was prepared using the procedures of Examples 1 and 9. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.23(d,J=8.4Hz,1H),7.55(d,J=9.0Hz,2H),7.46-7.35(m,1H),7.40(s,2H),7.28(d,J=7.6Hz,1H),4.41(q,J=7.0Hz,2H) ),3.02(dd,J=13.6,8.9Hz,1H),2.86(dd,J=13.6,6.0Hz,1H),2.71-2.55(m,1H),1.78-1.53(m,4H),1.00(t,J=7.4Hz,3H).

[0593] Example 83: Separation of the enantiomers of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (Compound 240 and Compound 241)

[0594] [ka]

[0595] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (racemic) (58 mg) was purified by chiral preparative HPLC (CHIRALPAK IC-3 column, 20 *250 mm, 5 um; mobile phase, 20 mL / min. Phase A: n-hexane / DCM=5 / 1, Phase B: ethanol (0.1% TFA)) separated into individual enantiomers. This gave (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (18 mg, 36%, ee%=99.5%) as a white solid, and (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)butanoic acid (17.8 mg, 36%, ee%=99.2%) as a white solid.

[0596] Data for compound 240 (peak 1): LCMS (ESI) = 434.2 [M+H] + .HPLC (CHIRALPAK IC-3, 4.6x50mm, 3μm, 1.0 mL / min); A: n-Hexane:DCM 5 / 1; B: EtOH w / 0.1% TFA; 25% B: t R =2.27 minutes. * The absolute stereochemistry of the isolated single enantiomers has not been determined.

[0597] Data for compound 241 (peak 2): LCMS (ESI) = 434.2 [M+H] + .HPLC (CHIRALPAK IC-3, 4.6x50mm, 3μm, 1.0 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA; 25% B):t R =2.78 minutes. * The absolute stereochemistry of the isolated single enantiomers has not been determined.

[0598] Example 84: Synthesis of ethyl 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoate (Compound 242)

[0599] [ka]

[0600] Ethyl 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoate was prepared from ethyl isobutyrate using the procedure of Example 82. LCMS (ESI) = 462.3 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ11.68(s,1H),7.93(d,J=8.3Hz,1H),7.63(d,J=7.9Hz,1H),7.51-7.31(m,4H),7.17(d,J=7.6Hz,1H),4.30( q,J=6.9Hz,2H),4.07(q,J=7.1Hz,2H),2.92(s,2H),1.41(t,J=6.9Hz,3H),1.18(t,J=7.1Hz,3H),1.16(s,6H).

[0601] Example 85: Synthesis of 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoic acid (Compound 243)

[0602] [ka]

[0603] 3-(3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)-2,2-dimethylpropanoic acid was prepared using the ester hydrolysis procedure of Example 9. LCMS (ESI) = 434.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ7.98(d,J=8.4Hz,1H),7.62(d,J=7.7Hz,1H),7.53(s,1H),7.46-7.31(m,3H),7.21(d ,J=7.5Hz,1H),4.31(q,J=6.8Hz,2H),2.90(s,2H),1.42(t,J=6.9Hz,3H),1.13(s,6H).

[0604] Example 86: Synthesis of 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclopropane-1-carboxylic acid (Compound 244)

[0605] [ka]

[0606] 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclopropane-1-carboxylic acid was prepared from tert-butyl cyclopropanecarboxylate using the procedures of Examples 82 and 58. LCMS (ESI) = 433.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.96(d,J=8.5Hz,1H),7.65(t,J=1.7Hz,1H),7.59(dt,J=7.7,1.6Hz,1H),7.46-7.29(m,4H),4.3 1(q,J=6.9Hz,2H),2.98(s,2H),1.42(t,J=6.9Hz,3H),1.15(q,J=3.7Hz,2H),0.89(q,J=3.9Hz,2H).

[0607] Example 87: Synthesis of ethyl 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylate (Compound 245)

[0608] [ka]

[0609] Ethyl 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylate was prepared using the procedure of Example 82. LCMS (ESI) = 474.3 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.07(s,1H),7.89(d,J=8.2Hz,1H),7.63(d,J=7.8Hz,1H),7.50(s,1H),7.47-7.32(m,3H),7.19(d,J=7.4Hz,1H),4.30(q,J=6.9Hz,2H) ,4.08(q,J=7.1Hz,2H),3.17(s,2H),2.40-2.28(m,2H),2.16-2.02(m,2H),1.99-1.72(m,2H),1.41(t,J=6.9Hz,3H),1.15(t,J=7.1Hz,3H).

[0610] Example 88: Synthesis of 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylic acid (Compound 246)

[0611] [ka]

[0612] 1-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)methyl)cyclobutane-1-carboxylic acid was prepared using the ester hydrolysis procedure of Example 9. LCMS (ESI) = 446.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.93(d,J=8.2Hz,1H),7.61(d,J=7.9Hz,1H),7.54(s,1H),7.46-7.32(m,3H),7.24(d,J=7.7Hz,1H),4.31( q,J=6.9Hz,2H),3.15(s,2H),2.39-2.22(m,2H),2.12-1.97(m,2H),1.96-1.71(m,2H),1.42(t,J=6.9Hz,3H.

[0613] Example 89: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 247)

[0614] [ka]

[0615] Dioxane (0.50 mL) and H 2 To a solution of methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)butanoate (prepared from methyl 2-bromobutanoate using the method of Example 56) (50.0 mg, 0.156 mmol, 1.00 equiv) and 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (52.5 mg, 0.156 mmol, 1.00 equiv) in 2H2O (0.10 mL) was added 10 mL of KCl. 2 CO 3 (64.8 mg, 0.468 mmol, 3.00 equiv.) and Pd(dppf)Cl2 (11.4 mg, 0.011 mmol, 0.10 equiv.) was added. After stirring at 100° C. under nitrogen atmosphere for 16 h, the resulting mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 2-((3′-ethoxy-4′-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)oxy)butanoic acid (15.7 mg, 23%) as an off-white solid. LCMS (ESI)=436.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.05(s,1H),7.88(d,J=8.4Hz,1H),7.38(dt,J=11.0,6.9Hz,4H),7.26(s,1H),6.95(d,J=8.1Hz,1H),4. 83(t,J=6.0Hz,1H),4.31(q,J=6.9Hz,2H),2.00-1.85(m,2H),1.40(t,J=6.9Hz,3H),1.05(t,J=7.4Hz,3H).

[0616] Example 90: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)pentanoic acid (Compound 248)

[0617] [ka]

[0618] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)pentanoic acid was prepared using the procedure of Example 89. LCMS (ESI) = 450.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ12.20(s,1H),7.86(d,J=8.2Hz,1H),7.48-7.31(m,4H),7.26(s,1H),6.94(d,J=8.1Hz,1H),4.87(t,J=6.3Hz,1H ),4.31(q,J=6.9Hz,2H),1.89(q,J=7.0Hz,2H),1.52(q,J=7.7Hz,2H),1.40(t,J=6.9Hz,3H),0.96(t,J=7.3Hz,3H).

[0619] Example 91: Synthesis of 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-phenylacetic acid (Compound 249)

[0620] [ka]

[0621] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)-2-phenylacetic acid was prepared from ethyl 2-bromo-2-phenylacetate using the procedure of Example 89. LCMS (ESI) = 484.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.93(d,J=8.0Hz,1H),7.66-7.57(m,2H),7.47-7.29(m,8H),7.05-6.96(m,1H),5.82(s,1H),4.31(q,J=6.9Hz,2H),1.41(t,J=6.9Hz,3H).

[0622] Example 92: Synthesis of 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 250)

[0623] [ka]

[0624] 2-((3'-(cyclopentyloxy)-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure of Example 89. 462.2 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ8.02(d,J=8.4Hz,1H),7.46-7.33(m,3H),7.33(d,J=7.7Hz,1H),7.23(t,J=2.1Hz,1H),6.93(ddd,J=8.1,2.6,1 .1Hz,1H),5.25-5.18(m,1H),4.94(d,J=7.5Hz,1H),2.02-1.80(m,4H),1.79-1.59(m,4H),1.54(d,J=6.7Hz,3H).

[0625] Example 93: Synthesis of (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 251)

[0626] [ka]

[0627] Step 1: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.00 g, 4.54 mmol, 1.00 equiv.), methyl (S)-2-hydroxypropanoate (0.52 g, 5.00 mmol, 1.10 equiv.), and PPh in THF (10 mL). 3 To a stirred solution of (1.55 g, 5.90 mmol, 1.30 equiv.) 2DIAD (1.19 g, 5.91 mmol, 1.30 equiv) was added dropwise under atmosphere at 0° C. The resulting mixture was stirred at room temperature for 16 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl (R)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (500 mg, 36%) as an off-white oil. LCMS (ESI)=307.2 [M+H] + .

[0628] Step 2: Dioxane (1.0 mL) and H 2 To a solution of methyl (R)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (90.0 mg, 0.294 mmol, 1.00 equiv) and 5-(4-bromo-2-ethoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (98.8 mg, 0.294 mmol, 1.0 equiv) in 20O (0.3 mL) was added K 2 CO 3 (122 mg, 0.882 mmol, 3.00 equiv.) and Pd(dppf)Cl 2 (21.5 mg, 0.029 mmol, 0.1 equiv) was added dropwise. After stirring at 100° C. for 16 h under nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC to give (R)-2-((3′-ethoxy-4′-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1′-biphenyl]-3-yl)oxy)propanoic acid (15.7 mg, 13%) as an off-white solid. LCMS (ESI)=422.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ7.97(d,J=8.5Hz,1H),7.40-7.25(m,4H),7.21(d,J=2.2Hz,1H),6.89(dd,J=8.7,1.9Hz,1H),4.77(d,J =6.9Hz,1H),4.31(q,J=7.0Hz,2H),1.49(d,J=6.7Hz,3H),1.42(t,J=6.9Hz,3H).Analytical chiral HPLC: CHIRALPAK AD-3 column [100 * 3 mm, 3 μm, 1.5 mL / min, 50% hexane:DCM (5:1)-100% EtOH (w / 0.1% TFA):t R 2.01 min (Peak 1).

[0629] Example 94: Synthesis of (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 252)

[0630] [ka]

[0631] (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from methyl (R)-2-hydroxypropanoate using the procedure of Example 89. LCMS (ESI) = 422.1 [M+H] + Analytical chiral HPLC: CHIRALPAK AD-3 column [100 * 3 mm, 3 μm, 1.5 mL / min, 50% hexane:DCM (5:1)-100% EtOH (w / 0.1% TFA) R 3.48 min (Peak 2).

[0632] Example 95: Synthesis of (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 253) and (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 254).

[0633] [ka]

[0634] 2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was purified using a CHIRALPAK IC-3 column, 20 * 250 mm, 5 μM. A: n-Hexane / DCM, 5 / 1. B: EtOH w / 0.1% TFA, 20% of B was used to purify into individual enantiomers.

[0635] Data for (R)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (peak 1): LCMS (ESI) = 436.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ12.21(s,1H),7.86(d,J=8.5Hz,1H),7.48-7.31(m,4H),7.26(t,J=2.1Hz,1H),6.99-6.90(m,1H),4.84(dd,J=6.8,5. 2Hz,1H),4.31(q,J=7.0Hz,2H),2.02-1.85(m,2H),1.39(t,J=6.9Hz,3H),1.04(t,J=7.4Hz,3H).Analytical chiral SFC: CHIRALPAK AD-3;100* 3.0 mm, 3 μm, EtOH (0.2% MSA), 1.5 mL / min; Pump B: 50.0%, t R =1.51 minutes.

[0636] Data for (S)-2-((3'-ethoxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (peak 2): LCMS (ESI) = 436.1 [M+H] + .Chiral SFC:CHIRALPAK AD-3;100 * 3.0 mm, 3 μm, EtOH (0.2% MSA), 1.5 mL / min; Pump B: 50.0%, t R =3.94 minutes.

[0637] Example 96A: Synthesis of (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 255)

[0638] [ka]

[0639] (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from methyl (R)-2-(3-bromo-5-hydroxyphenoxy)propanoate using the procedures of Examples 93, 42, and 9. LCMS (ESI) = 438.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ9.65(s,1H),7.93(d,J=8.2Hz,1H),7.31-7.22(m,2H),6.68(d,J=7.7Hz,2H),6.32(s,1H),4.82-4. 70(m,1H),4.29(q,J=6.8Hz,2H),1.49(d,J=6.7Hz,3H),1.41(t,J=6.9Hz,3H).Analytical chiral HPLC: CHIRALPAK AD-3(100x3mm, 3μm, 1.5mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA; 30%B):t R =1.96 min (Peak 1).

[0640] Example 96B: Synthesis of (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 256)

[0641] [ka]

[0642] (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from methyl (S)-2-(3-bromo-5-hydroxyphenoxy)propanoate using the procedure of Example 96A. LCMS (ESI) = 438.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ9.65(s,1H),7.93(d,J=8.2Hz,1H),7.31-7.22(m,2H),6.68(d,J=7.7Hz,2H),6.32(s,1H),4.82-4. 70(m,1H),4.29(q,J=6.8Hz,2H),1.49(d,J=6.7Hz,3H),1.41(t,J=6.9Hz,3H).Analytical chiral HPLC: CHIRALPAK AD-3(100x3mm, 3μm, 1.5mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA; 30%B):t R =2.68 min (Peak 2).

[0643] Example 97: Synthesis of 2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 257)

[0644] [ka]

[0645] 2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was prepared from methyl 2-bromobutanoate and 5-bromobenzene-1,3-diol using the procedures of Examples 42 and 9. LCMS (ESI) = 452.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.93(d,J=8.4Hz,1H),7.31-7.22(m,2H),6.68(dt,J=9.3,1.8Hz,2H),6.35(t,J=2.1Hz,1H),4.38(dd,J=7.1,5.1Hz ,1H),4.28(q,J=6.9Hz,2H),3.17(s,2H),1.82(dp,J=14.0,7.1Hz,2H),1.40(t,J=6.9Hz,3H),1.03(d,J=24.0Hz,8H).

[0646] Example 98: Synthesis of (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 258)

[0647] [ka]

[0648] (R)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was prepared from methyl (S)-2-hydroxybutanoate and 5-bromobenzene-1,3-diol using the procedures of Examples 93, 42, and 9. LCMS (ESI) = 452.1 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ9.72(s,1H),7.91(d,J=8.4Hz,1H),7.33-7.24(m,2H),6.70(dt,J=9.6,1.7Hz,2H),6.34(t,J=2.1Hz,1H),4.61(t,J=6 .2Hz,1H),4.29(q,J=6.9Hz,2H),1.97-1.77(m,2H),1.40(t,J=6.9Hz,3H),1.02(t,J=7.4Hz,3H).Analytical chiral HPLC: CHIRALPAK ID-3(50 * 4.6 mm, 3 μm, 1 mL / min; A: Hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA; 50%B):t R =1.57 min (Peak 1).

[0649] Example 99: Synthesis of (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid (Compound 259)

[0650] [ka]

[0651] (S)-2-((3'-ethoxy-5-hydroxy-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)butanoic acid was prepared by preparative chiral HPLC using a CHIRALPAK IC-3 column using the procedure of Example 95. LCMS (ESI) = 452.1 [M+H] + .Analytical Chiral HPLC: CHIRALPAK ID-3(50 * 4.6mm, 3um, 1mL / min); A: Hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA; 50% Bt R 2.43=min (Peak 2).

[0652] Example 100: Synthesis of (R)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 260)

[0653] [ka]

[0654] Step 1: 5-Bromo-2,3-difluorophenol (500 mg, 2.32 mmol, 1.00 equiv), methyl (S)-2-hydroxypropanoate (479 mg, 2.87 mmol, 1.2 equiv), PPh 3(816 mg, 3.11 mmol, 1.3 equiv.), and THF (10 mL) were added to a 50 ml round bottom flask. DIAD (629 mg, 3.11 mmol, 1.3 equiv.) was added to the above mixture at 0° C. over 15 min. The resulting mixture was stirred at room temperature for an additional 12 h, after which the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give methyl (R)-2-(5-bromo-2,3-difluorophenoxy)propanoate (450 mg, 58%) as a yellow oil. 1 H NMR (300MHz, DMSO-d 6 )δ7.37(ddd,J=9.7,6.3,2.3Hz,1H),7.23(dt,J=6.7,2.2Hz,1H),5.33-5.11(m,1H),3.70(s,3H),1.54(d,J=6.8Hz,3H).

[0655] Step 2: Methyl (R)-2-(5-bromo-2,3-difluorophenoxy)propanoate (300 mg, 1.02 mmol, 1.00 equiv) and bis(pinacolato)diboron (310 mg, 1.22 mmol, 1.2 equiv), KOAc (299 mg, 3.05 mmol, 3.0 equiv), dioxane (6.0 mL), Pd(dppf)Cl 2 (74.4 mg, 0.102 mmol, 0.10 equiv) was added to a 40 ml vial and the resulting mixture was stirred for 2 h at 100° C. The mixture was purified by silica gel column chromatography to give methyl (R)-2-(2,3-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (350 mg, 92%) as a yellow oil.

[0656] (R)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure of Example 89. LCMS (ESI) = 458.0 [M+H] + . 1H NMR (300MHz, DMSO-d 6 )δ7.89(d,J=7.9Hz,1H),7.42(ddd,J=11.6,6.7,2.0Hz,1H),7.39-7.29(m,2H),7.20(d,J=6.9Hz,1H),5.02(d, J=7.0Hz,1H),4.28(tt,J=7.0,3.9Hz,2H),1.52(d,J=6.7Hz,3H),1.39(t,J=6.9Hz,3H).Analytical chiral HPLC: CHIRALPAK IC-3(50 * 4.6 mm, 3 μm, 1 mL / min; A: n-hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA), 15% Bt R =1.72 min (Peak 1).

[0657] Example 101: Synthesis of (S)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 261)

[0658] [ka]

[0659] (S)-2-((3'-ethoxy-4,5-difluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared from methyl (R)-2-hydroxypropanoate using the procedure of Example 100. LCMS (ESI) = 458.0 [M+H] + . 1 H NMR (300MHz, DMSO-d 6)δ7.88(d,J=8.0Hz,1H),7.42(ddd,J=11.5,6.6,1.9Hz,1H),7.39-7.29(m,2H),7.20(d,J=6.9Hz,1H),5.01(q, J=6.7Hz,1H),4.28(qd,J=7.0,1.8Hz,2H),1.52(d,J=6.7Hz,3H),1.38(t,J=6.9Hz,3H).Analytical chiral HPLC: CHIRALPAK IC-3(50 * 4.6 mm, 3 μm, 1 mL / min; A: n-Hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA); 15% B).t R =3.79 min (Peak 2).

[0660] Example 102: Synthesis of (R)-2-((3'-ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 262)

[0661] [ka]

[0662] (R)-2-((3'-ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid was prepared using the procedure of Example 100. LCMS (ESI) = 440.0 [M+H] + . 1 H NMR (300MHz, DMSO-d 6 )δ7.93(d,J=8.5Hz,1H),7.43-7.35(m,2H),7.21(dt,J=9.9,1.9Hz,1H),7.12(t,J=1.9Hz,1H),6.77(dt,J=11.0,2.2Hz ,1H),4.89(d,J=7.0Hz,1H),4.32(q,J=6.9Hz,2H),1.51(d,J=6.7Hz,3H),1.40(t,J=6.9Hz,3H).Analytical chiral HPLC: CHIRALPAK IA-3(50* 4.6 mm, 3 μm, 1 mL / min); A: n-Hexane / DCM, 5 / 1; B: EtOH w / 0.1% TFA, 50%B).t R =0.923 min (Peak 1).

[0663] Example 103: Synthesis of (S)-2-((3'-ethoxy-5-fluoro-4'-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)-[1,1'-biphenyl]-3-yl)oxy)propanoic acid (Compound 263)

[0664] [ka] 【06...

Claims

1. A compound having the structure of formula (I″), or a pharma- ceutically acceptable salt or solvate thereof: 【Chemistry 1】 During the ceremony, R 1 is -CH 2 R 4 , -CN, -B(OH) 2 , -N(R 10 ) 2 , -NR 10 C(O)R 9 , -C(O)OH, -CH 2 C(O)OH, -C(O)N(R 10 ) 2 , -C(O)NHS(O) 2 N (R 10 ) 2 , -C 1-6 Alkyl-OH, C 3-8 Cycloalkyl, 【Chemistry 2】 Or one, two, or three R 8 is a 5- or 6-membered heteroaryl optionally substituted with a group; R 2 is H, -OH, -N(R 10 ) 2 , -NHS(O) 2 R 9 , -S(O) 2 N (R 10 ) 2 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -O-C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 is cycloalkyl, R 3 each independently represents a halogen, —CN, —OH, or —OR 9 , -SR 9 , -N(R 10 ) 2 , -NO 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N (R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and -C 1-6 Alkyl-C 3-8 cycloalkyl; R 4 teeth, 【Chemistry 3】 and R 5 each independently represents a halogen, —CN, —OH, or —OR 9 , -SR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N (R 10 ) 2 , -C(O)NHS(O) 2 N (R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-R 9 , -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 2-6 Alkenyl, -C 2-6 Alkenyl-C(O)OR 10 , C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl, wherein C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, —C(O)OR 10 , C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl, and 2-9 Heterocycloalkyl and -C 1-6 Alkyl-C 2-9 Heterocycloalkyl is halogen, —C(O)OR 10 , C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 6 は、-C(O)OR 7 、-C(O)NHS(O) 2 N(R 10 ) 2 、 【Chemistry 4】 and R 7 are independently H and C 1-6 alkyl, R 8 each independently represents a halogen, —OH, or —OR 9 , -N(R 10 ) 2 , -S(O)R 9 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N (R 10 ) 2 , -C(O)NHS(O) 2 N (R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , -NR 10 C(O)OR 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl, wherein phenyl, -C 1-6 Alkyl-phenyl, and C 1-9 Heteroaryl is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, and C 2-9 heterocycloalkyl, and 2-9 Heterocycloalkyl is halogen, C 1-6 Alkyl, C 1-6 optionally substituted with 1, 2, or 3 groups independently selected from haloalkyl, and oxo; R 9 are each independently 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, C 2-9 Heterocycloalkyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, -C 1-6 Alkyl-C 2-9 Heterocycloalkyl, C 2-9 Heteroaryl, and -C 1-6 Alkyl-C 2-9 Heteroaryl is C 1-6 Alkyl, -OR 11 , -N(R 11 ) 2 , C 1-6 Alkyl, C 3-8 Cycloalkyl, -N(R 11 ) C(O)R 12 , -C(O)R 12 and -C(O)OR 12 and optionally substituted with one or two groups independently selected from R 10 are each independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-8 Cycloalkyl, -C 1-6 Alkyl-C 3-8 Cycloalkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 heteroaryl, wherein C 1-6 Alkyl, phenyl, -C 1-6 Alkyl-phenyl, and C 2-9 Heteroaryl is halogen, C 1-6 Alkyl, -N(R 11 ) 2 and -C(O)OR 12 or optionally substituted with one or two groups independently selected from two R 10 and the nitrogen atom to which they are attached together form C 1-6 forming a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from alkyl, oxo, and -C(O)OH; R 11 are each independently H and C 1-6 alkyl, R 12 are each independently H and C 1-6 alkyl, R 13 are each independently 1-6 alkyl, m is 1, 2, 3, or 4; n is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 0, 1, 2, 3, or 4; The compound, or a pharma- ceutically acceptable salt or solvate thereof.

2. R 1 teeth 【Chemistry 5】 2. The compound of claim 1, wherein:

3. 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof, wherein p is 0, 1, or 2.

4. (i) R 5 each independently represents a halogen, —OH, or —OR 9 , -N(R 10 ) 2 , -S(O) 2 R 9 , -NHS(O) 2 R 9 , -S(O) 2 N (R 10 ) 2 , -C(O)NHS(O) 2 N (R 10 ) 2 , -C(O)R 9 , -C(O)OR 10 , -OC(O)R 9 , -C(O)N(R 10 ) 2 , -OC(O)N(R 10 ) 2 , -NR 10 C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-OR 9 , -C 1-6 Alkyl-N(R 10 ) 2 , -C 1-6 Alkyl-C(O)OR 10 , C 1-6 Haloalkyl, C 1-6 Haloalkyl-OH, C 3-8 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; (ii) R 5 each independently represents a halogen, —OH, or —OR 9 , -N(R 10 ) 2 , -C(O)NHS(O) 2 N (R 10 ) 2 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , -NR 10 C(O)R 9 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and C 1-9 heteroaryl; (iii) R 5 each independently represents a halogen, —OH, or —OR 9 , -C(O)OR 10 , -C(O)N(R 10 ) 2 , C 1-6 Alkyl, -C 1-6 Alkyl-C(O)OR 10 , and 【Chemistry 6】 is selected from (iv) R 5 are each independently a halogen, —OH, or —C(O)OR 10 or (v) R 5 each independently represents a halogen, —OH, or —OR 9 , and -C 1-6 Alkyl-C(O)OR 10 4. The compound according to any one of claims 1 to 3, selected from: or a pharma- ceutically acceptable salt or solvate thereof.

5. R 9 is -C(O)OR 12 C optionally substituted with 1-6 5. The compound of claim 4, or a pharma- ceutically acceptable salt or solvate thereof, wherein: R is an alkyl group;

6. R 10 are each independently H and C 1-6 6. The compound of any one of claims 1-5, or a pharma- ceutically acceptable salt or solvate thereof, wherein: R is selected from the group consisting of alkyl, aryl ... and aryl;

7. R 1 is one, two, or three R 8 2. The compound of claim 1, or a pharma- ceutically acceptable salt or solvate thereof, wherein R is a 5- or 6-membered heteroaryl optionally substituted with a group.

8. R 1 is one or two R 8 8. The compound of claim 7, or a pharma- ceutically acceptable salt or solvate thereof, wherein the 5-membered heteroaryl is selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, tetrazolyl, and isoxazolyl, optionally substituted with a group.

9. R 1 is one or two R 8 8. The compound of claim 7, or a pharma- ceutically acceptable salt or solvate thereof, wherein: R is a 6-membered heteroaryl optionally substituted with a group, wherein the 6-membered heteroaryl is selected from pyridinyl and pyrimidinyl.

10. R 8 each independently represents a halogen, -C(O)OR 10 , C 1-6 Alkyl, and -C 1-6 Alkyl-C(O)OR 10 10. The compound according to any one of claims 7 to 9, selected from: or a pharma- ceutically acceptable salt or solvate thereof.

11. (i) R 2 is H, -OH, -N(R 10 ) 2 or -O-C 1-6 is alkyl, or (ii) R 2 Ha-OCH 2 CH 3 11. The compound of any one of claims 1-10, which is: or a pharma- ceutically acceptable salt or solvate thereof.

12. 12. The compound of any one of claims 1-11, or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0. 【Request 13】 【Chemical 7-1】 【Chemistry 7-2】 【Chemistry 7-3】 【Chemistry 7-4】 【Chemistry 7-5】 【Chemistry 7-6】 【Chemistry 7-7】 【Chemistry 7-8】 【Chemistry 7-9】 【Chemistry 7-10】 【Chemical 7-11】 【Chemistry 7-12】 or a pharma- ceutically acceptable salt or solvate thereof.

14. A pharmaceutical composition comprising a compound according to any one of claims 1-13, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient.

15. 16. Use of a compound according to any one of claims 1-13, or a pharma- ceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating inflammatory bowel disease in a patient and in the manufacture of a medicament for modulating GPR35 activity, optionally wherein the inflammatory bowel disease is selected from Crohn's disease, ulcerative colitis, and perianal Crohn's disease.

16. 15. The pharmaceutical composition of claim 14 for use in treating inflammatory bowel disease in a patient and modulating GPR35 activity, optionally wherein the inflammatory bowel disease is selected from Crohn's disease, ulcerative colitis, and perianal Crohn's disease.

Citation Information

Patent Citations

  • Use of 8-azapurin-6-one derivatives for control of hypertension

    US4923874A

  • Immune system modulators

    US9353115B2

  • Pharmaceutical compounds specifically inhibiting smooth muscle PDE5, pharmaceutical compositions containing same and therapeutic uses thereof

    WO2004035584A1

  • Screening method for emulators of neural activity and digestive system using GPR35

    WO2005085867A2